Details of the Drug

General Information of Drug (ID: DMQNWRD)

Drug Name
Oxaliplatin
Synonyms Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Appendiceal neoplasm N.A. Approved [1]
Cholangiocarcinoma 2C12.10 Approved [1]
Colon adenocarcinoma N.A. Approved [1]
Colorectal cancer 2B91.Z Approved [2]
Colorectal carcinoma N.A. Approved [1]
Endocrine gland neoplasm N.A. Approved [1]
Gallbladder carcinoma N.A. Approved [1]
Metastasis from malignant tumor of colon N.A. Approved [1]
Nasopharyngeal carcinoma 2B6B Approved [1]
Peritoneal neoplasm N.A. Approved [1]
Rectal adenocarcinoma 2B92 Approved [1]
Rectal neoplasm N.A. Approved [1]
Rectum mucinous adenocarcinoma N.A. Approved [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01XA03: Oxaliplatin
L01XA: Platinum compounds
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 397.29
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The renal clearance of drug is 10-17 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 0.43 hours (alpha), and 16.8 hours (beta) [4]
Metabolism
The drug is metabolized via the displacement of the labile oxalate ligand []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.1315 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [4]
Vd
The volume of distribution (Vd) of drug is 440 L []
Water Solubility
The ability of drug to dissolve in water is measured as 6 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Neuropathy peripheral rs10486003 TAC1 OTM842YW [6]
Chemical Identifiers
Formula
C8H14N2O4Pt
IUPAC Name
[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
Canonical SMILES
C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
InChI
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
InChIKey
DRMCATBEKSVAPL-BNTLRKBRSA-N
Cross-matching ID
PubChem CID
9887053
CAS Number
61825-94-3
UNII
04ZR38536J
DrugBank ID
DB00526
TTD ID
D0Y3ME
VARIDT ID
DR00316
INTEDE ID
DR1210
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [8]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [13]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [13]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [13]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [14]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [14]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Substrate [14]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [14]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Substrate [14]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Substrate [14]
Superoxide dismutase 1 (SOD1) DEUTDON SODC_HUMAN Substrate [14]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [14]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Drug Response [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 6.4096 9.1998 3.3246 2.0454
EW-12 GDSC2 1.865 5.9846 0.6424 21.5376
EW-22 GDSC2 2.3383 5.4666 1.7643 20.9465
EW-3 GDSC2 2.8147 5.8843 2.09 17.4598
ES1 GDSC2 2.9081 5.3381 1.9511 9.9603
SK-ES-1 GDSC2; CTRP2 3.2258 4.8239 3.1963 18.8772
ES7 GDSC2 3.382 6.4685 2.3914 13.8595
ES8 GDSC2 3.8139 6.9676 2.5551 11.5845
SK-PN-DW GDSC2 3.9908 6.7088 2.8425 9.428
Hs 888.T CTRP2 4.2686 17.461 -1.2039 29.8908
EW-13 GDSC2 4.4498 7.0635 3.0562 6.9513
CHSA0011 GDSC2 4.5156 8.2328 1.776 6.7904
A-673 GDSC2; CTRP2 4.6174 7.2476 4.0494 11.6212
CADO-ES1 GDSC2 4.7371 7.8884 2.8718 7.3047
EW-11 GDSC2 5.1266 10.1566 2.0451 11.001
EW-7 GDSC2 5.361 9.2471 2.6624 7.11
CAL-72 GDSC2 5.545 8.9778 2.9174 5.358
ES6 GDSC2 5.5467 8.0391 3.3577 3.025
EW-24 GDSC2 5.6478 8.7519 3.0903 4.2516
U-CH2 GDSC2 5.7222 8.4671 2.3678 1.7122
SK-N-MC CTRP2 5.7491 6.3289 5.6165 2.4641
ES5 GDSC2 5.7828 10.5879 2.3069 8.1877
TC-71 GDSC2 5.8175 7.6848 3.6627 1.2306
HuO-3N1 GDSC2 5.8589 8.4351 3.361 2.552
CHSA0108 GDSC2 5.8938 8.9503 2.2523 2.039
EW-16 GDSC2 5.939 8.314 3.4579 1.9926
SJSA-1 GDSC2; CTRP2 6.1142 9.4991 3.6332 5.3358
EW-1 GDSC2 6.2355 10.1361 2.8125 4.7305
TC71 CTRP2 6.3357 7.4365 5.5736 1.4824
H-EMC-SS GDSC2 6.4393 10.7644 2.6476 5.245
CHSA8926 GDSC2 6.4621 14.1122 1.0753 12.9993
EW-18 GDSC2 6.5976 9.5692 3.2643 2.1021
HOS GDSC2; CTRP2 6.6364 11.2551 3.9144 7.8652
SaOS-2 GDSC2; CTRP2 6.6782 8.3789 5.3537 1.8837
NY GDSC2 6.6842 8.7951 3.6158 0.719
MHH-ES-1 GDSC2; CTRP2 6.8146 8.3133 5.4694 1.2727
SW1353 CTRP2 6.8894 8.6522 5.3593 2.1805
ES4 GDSC2 6.8953 13.8325 1.5023 10.1589
HuO9 GDSC2 7.0334 9.5893 3.4604 0.9841
Hs 822.T CTRP2 7.0386 8.7133 5.4191 1.219
NOS-1 [Human HNSCC] GDSC2 7.2438 9.6399 3.5292 0.66
CAL-78 GDSC2; CTRP2 7.4685 8.8549 5.5749 0.4184
MG-63 GDSC2; CTRP2 7.7251 11.5797 4.5205 3.7945
G-292 clone A141B1 GDSC2; CTRP2 7.8061 10.1898 5.1904 1.3005
U2OS GDSC2; CTRP2 7.9098 10.5037 5.1104 1.7424
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 218 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 2.2146 5.2159 2.0584 26.0473
MEC1 CTRP2 4.9591 6.706 4.631 8.4352
JM1 GDSC2; CTRP2 2.3454 4.3129 2.3171 24.7382
BV-173 GDSC2 -1.1663 0.4763 -1.17 45.0537
NKM-1 GDSC2 -0.7615 1.042 -0.7728 41.0283
KMS-12-BM GDSC2; CTRP2 -0.3579 2.1188 -0.3655 42.6747
EB1 CTRP2 -0.0851 2.4016 -0.0951 40.8662
697 GDSC2; CTRP2 0.0138 1.8235 0.0127 40.1801
MOLT-3 CTRP2 0.1988 2.0368 0.1973 38.9491
GA-10 GDSC2; CTRP2 0.4393 2.7124 0.4302 37.3714
Namalwa GDSC2; CTRP2 0.6041 3.6371 0.5515 36.4118
MOLM-13 GDSC2; CTRP2 0.7097 2.5651 0.7067 42.0576
NU-DUL-1 GDSC2; CTRP2 0.8179 2.6468 0.7857 25.1723
EoL-1 GDSC2 0.8222 2.4698 0.8082 31.9809
HAL-01 GDSC2 0.9258 2.5466 0.9111 31.0396
IM-9 GDSC2 0.9875 3.1261 0.9262 30.69
NU-DHL-1 CTRP2 0.9987 4.0032 0.932 33.8337
KOPN-8 GDSC2 1.0197 2.9865 0.976 30.3159
BONNA-12 GDSC2 1.037 3.6848 0.7206 24.6005
SU-DHL-16 GDSC2 1.045 1.8414 1.0437 22.8557
Kasumi-2 CTRP2 1.0699 3.3114 1.0544 33.1923
KMS-28BM CTRP2 1.1575 6.9933 0.4248 34.7784
SU-DHL-5 GDSC2 1.1774 2.3723 1.174 28.6934
NALM-6 GDSC2; CTRP2 1.1995 2.9819 1.1953 32.2914
ML-2 GDSC2 1.2024 3.7093 1.0631 29.0939
OCI-AML-3 GDSC2; CTRP2 1.3371 3.5736 1.3174 31.4264
SUP-M2 GDSC2; CTRP2 1.3428 3.266 1.3347 31.3494
CTB-1 GDSC2 1.4082 3.806 1.0837 20.9467
Daudi GDSC2; CTRP2 1.4099 3.5946 1.3913 30.9377
NB4 GDSC2 1.4127 2.3044 1.4054 19.1957
MHH-CALL-2 GDSC2 1.425 4.3094 1.1638 27.6442
KMS-21-BM CTRP2 1.4253 3.5777 1.4079 42.0191
OCI-Ly3 CTRP2 1.4367 4.0462 1.3886 30.8575
KE-37 GDSC2; CTRP2 1.4622 3.672 1.4413 36.1958
A3/Kawakami GDSC2; CTRP2 1.4728 1.8391 1.4728 30.4568
YT GDSC2 1.5121 3.5392 1.2835 19.3783
Farage GDSC2 1.5173 3.6794 1.4096 26.0805
MY-M12 GDSC2 1.6303 3.6681 1.3709 18.3668
RS4;11 GDSC2 1.6801 3.396 1.6288 24.3304
SUP-B8 GDSC2 1.6885 3.5657 1.4673 17.5729
RPMI-6666 GDSC2; CTRP2 1.6951 4.0258 1.6606 29.0911
AMO1 GDSC2; CTRP2 1.7228 5.7652 1.4013 29.8719
BC-1 GDSC2 1.7966 4.5264 1.5076 24.4125
CTV-1 GDSC2 1.8006 4.1769 1.6086 23.9047
Granta-519 GDSC2; CTRP2 1.8149 5.1341 1.6414 28.764
RPMI-8226 GDSC2 1.8434 5.5322 1.2116 25.6571
WSU-NHL GDSC2 1.8492 3.6315 1.7757 22.8936
OCI-Ly19 GDSC2; CTRP2 1.8529 3.483 1.8477 27.9419
Karpas-1106P GDSC2 1.8885 5.3601 1.3248 24.9261
Pfeiffer CTRP2 1.8926 5.3284 1.6869 28.3577
KMS-34 CTRP2 1.8932 3.2371 1.8918 27.6603
BALL-1 GDSC2 1.967 4.1027 1.8083 22.2284
SEM CTRP2 2.0351 3.1988 2.0345 26.7126
MHH-CALL-4 GDSC2; CTRP2 2.0556 4.1327 2.0282 26.6657
MLMA GDSC2 2.0958 4.8289 1.7373 22.0439
WIL2 NS GDSC2 2.1334 3.9155 2.031 20.4405
MOLT-16 GDSC2; CTRP2 2.1496 3.3919 2.1485 25.9512
SUP-B15 GDSC2; CTRP2 2.1883 4.519 2.1337 25.8739
THP-1 GDSC2; CTRP2 2.2705 4.4188 2.2301 25.2781
KMS-26 CTRP2 2.2786 4.6108 2.2192 25.2885
P30/OHK GDSC2 2.2857 4.1386 2.147 19.2283
DoHH2 GDSC2; CTRP2 2.3001 3.8517 2.2931 29.5395
QIMR-WIL GDSC2 2.3113 5.1667 1.4643 15.059
Hs 445 GDSC2 2.3221 4.5696 2.0671 19.4717
SET-2 CTRP2 2.3531 4.1957 2.3328 24.6598
DEL GDSC2; CTRP2 2.3572 4.1272 2.3408 29.1264
P12-Ichikawa GDSC2; CTRP2 2.3666 4.2365 2.3443 29.0755
LC4-1 GDSC2 2.3696 5.399 1.8241 20.5189
Mono-Mac-1 CTRP2 2.3753 4.702 2.311 24.6614
KYO-1 CTRP2 2.4177 4.2619 2.3957 24.2352
CRO-AP2 GDSC2 2.5022 4.0085 2.1779 10.044
DB GDSC2; CTRP2 2.5129 5.4683 2.331 24.1521
HuT 78 CTRP2 2.5565 6.4664 2.1148 24.7809
KY821 GDSC2 2.5681 4.1921 2.4417 16.5957
CML-T1 GDSC2; CTRP2 2.6148 4.7362 2.561 27.2458
OCI-Ly7 GDSC2 2.6326 3.5307 2.5039 7.6139
SUP-T11 CTRP2 2.6689 6.0716 2.3531 23.5878
BC-3 GDSC2 2.6806 4.1537 2.2984 8.6231
EB2 GDSC2 2.7084 5.0106 2.3345 16.5701
OCI-AML-2 GDSC2 2.7241 4.0897 2.6356 14.9898
KE-97 CTRP2 2.781 6.8212 2.2442 23.6389
RC-K8 GDSC2 2.8127 6.2746 1.9154 18.3951
ROS-50 GDSC2 2.8384 5.3192 1.8964 10.5351
Hs 611.T CTRP2 2.8689 5.7841 2.6463 21.9268
SU-DHL-1 GDSC2; CTRP2 2.8904 4.6308 2.8614 24.9747
P32/ISH GDSC2 2.9447 4.6963 2.7022 13.7497
SCC-3 GDSC2 2.965 4.3708 2.8274 13.0359
TK [Human B-cell lymphoma] GDSC2 2.9663 5.0565 2.5927 14.2325
MV4-11 GDSC2; CTRP2 2.9706 4.5859 2.9485 20.5524
CESS GDSC2 2.9904 5.1202 2.5932 14.1385
JVM-2 GDSC2; CTRP2 2.9946 6.9911 2.4168 24.0226
MOLP-8 GDSC2; CTRP2 3.0114 5.4173 2.8821 20.6496
SKM-1 GDSC2 3.0356 5.5275 2.4722 14.6138
RCH-ACV GDSC2; CTRP2 3.0677 5.5115 2.9243 20.3239
JURL-MK1 GDSC2; CTRP2 3.1329 5.2194 3.0482 23.2889
NK-92MI GDSC2 3.2492 5.1278 2.3577 6.3199
JSC-1 GDSC2 3.2568 6.7111 2.1547 15.5763
OCI-AML-5 GDSC2; CTRP2 3.2636 5.5707 3.1246 19.0043
CA46 GDSC2; CTRP2 3.3389 7.5294 2.5859 20.7589
JVM-3 GDSC2; CTRP2 3.3719 6.3979 3.0241 22.5134
Ri-1 CTRP2 3.4005 6.6393 2.9771 19.1232
PL-21 GDSC2 3.4258 7.2633 1.4371 11.58
KMS-11 GDSC2 3.4334 6.8796 1.6351 10.3353
MN-60 GDSC2 3.4403 7.1747 2.1075 15.239
ALL-SIL GDSC2; CTRP2 3.4961 6.4857 3.1314 21.6123
VAL GDSC2 3.5421 5.5726 2.9686 10.1264
MHH-CALL-3 CTRP2 3.5727 7.3437 2.907 18.8903
Ku812 GDSC2; CTRP2 3.6328 6.0546 3.4098 16.8466
GR-ST GDSC2 3.6508 8.5112 1.6447 17.0835
Reh GDSC2 3.6508 6.3932 2.685 11.3534
SK-MM-2 GDSC2; CTRP2 3.6584 5.5136 3.382 13.1374
MOLM-6 CTRP2 3.6825 6.9244 3.1824 17.5395
ARH-77 GDSC2 3.7139 6.2265 2.8252 10.3644
RPMI-8866 GDSC2 3.7272 6.2525 2.8251 10.3234
U-698-M GDSC2 3.7355 7.1151 2.4109 12.634
RPMI-8402 GDSC2; CTRP2 3.7407 5.7364 3.6072 18.7026
NCO2 CTRP2 3.754 6.6629 3.3522 22.7484
Toledo CTRP2 3.8047 7.9081 2.9237 18.1853
H9 GDSC2 3.806 8.1706 1.9524 14.9678
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 3.8098 8.6375 2.6139 19.3626
Karpas-231 GDSC2 3.8589 6.4621 2.8451 9.8045
CCRF-CEM GDSC2 3.8858 6.5309 2.8359 9.7757
KMS-27 CTRP2 3.8859 6.0652 3.6831 15.0902
Peer CTRP2 3.8952 7.6852 3.1113 23.3889
Ki-JK CTRP2 3.9101 7.5979 3.1629 23.0757
HEL GDSC2; CTRP2 3.9389 5.3985 3.8853 15.262
Kasumi-1 GDSC2; CTRP2 4.0605 8.1829 3.0708 16.9318
AML-193 CTRP2 4.0707 8.3235 3.0194 17.1055
EHEB CTRP2 4.1516 8.3076 3.1091 22.4318
OPM-2 GDSC2; CTRP2 4.1537 6.9379 3.683 14.3084
U-937 CTRP2 4.1562 6.4831 3.8492 13.676
MHH-PREB-1 GDSC2 4.1679 7.1301 2.7875 9.2407
KM-H2 GDSC2; CTRP2 4.1896 6.6616 3.8235 14.6883
P31/FUJ GDSC2; CTRP2 4.2246 7.7933 3.409 17.9408
MEG-01 GDSC2 4.3179 7.1042 2.9274 8.0328
HPB-ALL CTRP2 4.3284 10.5187 2.2547 19.4163
EM-2 GDSC2; CTRP2 4.3343 6.3382 4.0903 14.5041
BE-13 GDSC2 4.3589 10.1855 1.4208 16.2169
ST486 GDSC2; CTRP2 4.3661 6.8513 3.9431 12.7208
A4/Fukuda GDSC2; CTRP2 4.3722 6.1853 4.1791 11.8211
SIG-M5 GDSC2; CTRP2 4.4433 5.9362 4.3254 11.0765
WSU-DLCL2 GDSC2; CTRP2 4.478 6.8577 4.0601 14.1502
SU-DHL-4 GDSC2; CTRP2 4.4858 7.2376 3.916 12.4956
HC-1 GDSC2 4.4895 7.5003 2.8702 7.9172
KMS-18 CTRP2 4.5561 8.4583 3.449 14.1627
SUP-HD1 GDSC2; CTRP2 4.5692 7.491 3.8956 12.3526
BL-41 GDSC2; CTRP2 4.5971 7.6421 3.8586 12.4252
MOLT-13 GDSC2 4.634 6.3607 3.5495 3.6849
GDM-1 GDSC2; CTRP2 4.6655 8.1888 3.6822 12.954
NOMO-1 GDSC2 4.6842 6.9586 3.292 5.0354
L-1236 GDSC2 4.695 11.4661 1.0558 17.1302
Jiyoye GDSC2 4.7194 8.8544 2.3778 10.1388
Karpas-422 GDSC2; CTRP2 4.7326 7.9811 3.8444 12.1348
HuNS1 CTRP2 4.836 8.5612 3.6774 12.5536
SU-DHL-10 GDSC2; CTRP2 4.8546 6.9679 4.4143 9.5597
DND-41 GDSC2; CTRP2 4.9295 9.3748 3.3783 13.5478
L-540 GDSC2; CTRP2 5.0022 7.4637 4.3507 9.4248
SU-DHL-8 GDSC2; CTRP2 5.0633 6.6531 4.7625 7.6417
MM1.S GDSC2; CTRP2 5.1127 8.2461 4.0956 10.1864
Mono-Mac-6 GDSC2; CTRP2 5.1235 10.335 3.0905 14.2745
HT GDSC2; CTRP2 5.1658 8.3751 4.085 11.9514
LAMA-84 GDSC2; CTRP2 5.1776 8.0814 4.2367 10.1554
KG-1 GDSC2 5.2192 8.4444 2.9521 5.7991
Karpas-620 GDSC2; CTRP2 5.224 7.3825 4.6103 7.8241
HEL 92.1.7 CTRP2 5.2493 9.7956 3.471 12.4419
Jurkat GDSC2; CTRP2 5.2498 7.5217 4.5713 8.5046
DG-75 GDSC2 5.2646 8.9883 2.72 6.9911
JeKo-1 GDSC2; CTRP2 5.285 7.4609 4.6344 7.5761
Ci-1 CTRP2 5.302 6.2279 5.1775 5.3912
ME1 GDSC2 5.3064 8.0276 3.2114 4.2085
HL-60 GDSC2; CTRP2 5.3154 7.0795 4.8405 6.6691
Loucy GDSC2 5.3291 11.273 1.6459 12.6396
MOLP-2 CTRP2 5.3528 7.4208 4.7198 7.0639
SUP-T1 GDSC2; CTRP2 5.3655 7.8295 4.5379 7.7773
RL GDSC2; CTRP2 5.3669 7.6166 4.641 7.3514
TF-1 CTRP2 5.4151 6.9174 5.0145 5.7197
KO52 CTRP2 5.4654 7.0614 4.9987 5.6577
SU-DHL-6 GDSC2; CTRP2 5.4899 7.6246 4.7552 6.5935
SR GDSC2; CTRP2 5.4939 6.9207 5.092 5.21
VL51 GDSC2 5.5307 8.2847 3.2345 3.6911
REC-1 CTRP2 5.5863 9.5999 3.8718 10.0526
BL-70 CTRP2 5.5912 6.1 5.5336 3.223
PF-382 GDSC2; CTRP2 5.6609 8.9032 4.284 8.174
Ramos.2G6.4C10 GDSC2 5.6706 8.3171 3.305 3.1024
K-562 GDSC2; CTRP2 5.7393 6.5365 5.5137 2.8991
KCL-22 GDSC2; CTRP2 5.748 8.4995 4.5619 7.3342
L-428 GDSC2; CTRP2 5.7916 9.0017 4.3501 7.6247
KMOE-2 GDSC2 5.7958 11.2068 2.017 9.6943
JJN-3 GDSC2; CTRP2 5.8122 9.7772 3.9811 9.1284
ATN-1 GDSC2 5.9126 7.9975 3.5794 1.4839
M-07e CTRP2 5.9245 8.4765 4.7271 5.7729
HD-MY-Z CTRP2 5.9544 8.2976 4.8419 5.2308
Karpas-45 GDSC2 5.9592 10.0072 2.7005 5.7691
Karpas-299 GDSC2; CTRP2 5.9896 8.3814 4.8299 5.2116
PL21 CTRP2 5.9921 8.0721 4.9867 4.5479
OCI-M1 GDSC2; CTRP2 5.9979 7.0148 5.5199 2.2958
Raji GDSC2; CTRP2 6.0073 7.4086 5.3311 3.0705
CMK CTRP2 6.0363 9.7632 4.1782 7.8581
TUR GDSC2 6.0981 8.1501 3.6074 1.185
F-36P CTRP2 6.1361 11.7297 3.2778 11.4083
MOTN-1 CTRP2 6.1467 7.6268 5.3367 2.7829
KMS-20 CTRP2 6.2166 9.3937 4.511 6.1204
EJM GDSC2; CTRP2 6.2916 9.5251 4.5055 6.0068
LP-1 GDSC2; CTRP2 6.4334 7.9407 5.3977 2.0532
KHM-1B CTRP2 6.4704 10.1722 4.3238 8.7769
MOLT-4 GDSC2 6.499 8.0608 3.8128 0.2962
HH [Human lymphoma] GDSC2 6.5276 9.2379 3.3678 1.7399
ALL-PO GDSC2 6.5953 9.8579 3.1402 2.6502
MOLM-16 GDSC2; CTRP2 6.6132 8.3079 5.3444 2.0088
P3HR-1 CTRP2 6.8266 9.0525 5.1317 2.5632
U266B1 GDSC2; CTRP2 6.8464 10.8787 4.2587 6.0902
OCI-Ly10 CTRP2 6.8715 16.8322 1.3233 17.4004
HDLM-2 GDSC2; CTRP2 6.8894 9.5048 4.9577 3.1713
MC116 GDSC2; CTRP2 7.0893 7.8593 5.7927 0.1155
NCI-H929 GDSC2; CTRP2 7.4703 11.3377 4.4709 4.3138
ME1 CTRP2 7.6716 12.9309 3.8447 6.5219
L-363 GDSC2 7.8821 16.5234 0.8716 11.3002
KMM-1 CTRP2 9.0085 11.4196 5.2475 0.6476
⏷ Show the Full List of 218 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 5.483 13.1987 1.3267 18.9764
TE15 CTRP2 5.874 11.2487 3.2989 11.8355
TE-5 GDSC2; CTRP2 4.3013 8.3649 3.2356 15.6574
T.T GDSC2 4.6047 6.5511 2.6095 1.8766
TE-15 GDSC2 5.2263 9.0789 2.6485 7.4679
KYSE-270 GDSC2 5.3891 9.6841 2.4698 8.1087
TE-4 GDSC2; CTRP2 5.4599 7.573 4.1075 4.1162
TE-6 GDSC2; CTRP2 5.6201 8.5886 3.7262 5.8088
TE-11 GDSC2; CTRP2 5.8975 7.266 5.3073 3.394
TE-8 GDSC2 5.9782 10.4767 2.4912 6.838
OE21 GDSC2; CTRP2 6.135 9.4978 4.3926 6.7695
KYSE-70 GDSC2; CTRP2 6.3029 8.4163 5.0664 3.6381
KYSE-510 GDSC2; CTRP2 6.402 9.7824 4.4644 5.982
KYSE-180 GDSC2; CTRP2 6.568 7.9958 5.4629 1.599
TE-10 GDSC2; CTRP2 6.6187 9.0893 4.97 3.5211
OE33 GDSC2; CTRP2 6.7414 12.7754 3.2407 10.4466
KYSE-140 GDSC2; CTRP2 7.1374 11.5982 4.1173 6.2137
EC-GI-10 GDSC2; CTRP2 7.5696 11.6231 4.4008 4.4583
KYSE-450 GDSC2; CTRP2 7.5795 8.9403 5.5897 0.3322
COLO 680N GDSC2; CTRP2 7.5884 12.3058 4.0882 6.6938
KYSE-30 CTRP2 7.678 10.9155 4.7981 2.7991
TE-1 GDSC2; CTRP2 7.6822 11.6385 4.466 4.0579
KYSE-410 GDSC2; CTRP2 7.7998 11.741 4.4922 3.8117
KYSE-150 GDSC2; CTRP2 8.0819 9.5225 5.5754 0.191
OE19 GDSC2; CTRP2 8.2475 9.5587 5.6234 0.0979
KYSE-520 GDSC2; CTRP2 8.5234 10.6118 5.3512 0.4501
TE-9 GDSC2; CTRP2 8.7513 10.0532 5.6306 0.0408
TE-14 CTRP2 10.0472 19.8706 2.1146 9.7811
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 6.9566 9.8104 4.8567 3.4818
KP-4 GDSC2; CTRP2 3.3978 6.1388 3.1298 21.9092
PSN1 GDSC2; CTRP2 3.5692 6.8368 3.0917 18.2054
PL4 GDSC2 4.94 10.3145 1.8238 12.5895
MIA PaCa-2 GDSC2; CTRP2 5.0477 8.7423 3.7956 11.5674
PANC-1 CTRP2 5.1174 20.9042 -2.1715 30.0588
PaTu 8988s CTRP2 5.3221 14.0247 1.4374 20.0996
MZ-PC-1 GDSC2 5.3483 7.8291 2.4492 1.7354
SU.86.86 GDSC2; CTRP2 6.064 10.0147 3.3492 6.8784
HuP-T3 GDSC2; CTRP2 6.0813 10.6626 3.766 9.4958
Panc 04.03 GDSC2; CTRP2 6.1223 7.443 5.4089 2.5247
KP-1N GDSC2 6.1229 9.5054 3.0327 3.7801
SW1990 GDSC2; CTRP2 6.2744 10.0821 4.2139 7.2598
PK-59 CTRP2 6.2891 10.3956 4.0691 7.8388
KP-3 GDSC2; CTRP2 6.3022 9.7438 4.4049 6.4091
SNU-410 CTRP2 6.3924 8.3536 5.1654 3.0751
Panc 08.13 GDSC2; CTRP2 6.5304 9.4329 4.7361 4.6293
PaTu 8902 GDSC2; CTRP2 6.5607 8.9321 5.0049 3.4679
Capan-1 GDSC2; CTRP2 6.5824 10.0913 4.45 5.732
TCC-Pan2 CTRP2 6.6363 10.1881 4.4427 5.672
YAPC GDSC2; CTRP2 6.6899 10.5623 4.2983 6.1824
BxPC-3 GDSC2; CTRP2 6.7508 11.074 4.0913 8.1744
HuP-T4 GDSC2; CTRP2 6.8243 9.5851 4.8743 3.6012
Panc 05.04 CTRP2 7.0749 10.8732 4.4256 5.0532
Panc 10.05 GDSC2; CTRP2 7.217 11.7073 4.1206 6.0791
AsPC-1 GDSC2; CTRP2 7.2509 10.0226 4.9483 2.7328
SNU-213 CTRP2 7.27 8.7851 5.5105 0.9782
Panc 02.03 GDSC2; CTRP2 7.4913 9.7599 5.2088 1.5143
HPAC GDSC2; CTRP2 7.6228 11.1417 4.6603 3.3834
PK-45H CTRP2 7.6782 14.0764 3.2951 8.6945
PaTu 8988t GDSC2; CTRP2 7.7275 9.1559 5.5698 0.3136
Hs 766T GDSC2; CTRP2 7.8146 13.845 3.5026 7.6716
HPAF-II GDSC2; CTRP2 7.8667 11.036 4.8539 2.8299
Panc 03.27 GDSC2; CTRP2 7.9131 12.9019 4.02 5.4972
L3.3 CTRP2 7.9206 9.1076 5.6616 0.1099
QGP-1 GDSC2; CTRP2 7.9862 12.4036 4.3006 5.1004
SUIT-2 GDSC2; CTRP2 8.1389 12.632 4.2893 4.1764
KP-2 GDSC2; CTRP2 8.1725 9.4297 5.6409 0.0913
CFPAC-1 GDSC2; CTRP2 8.3495 9.7666 5.5883 0.1402
Capan-2 GDSC2; CTRP2 8.3539 14.1965 3.6949 6.18
DAN-G GDSC2; CTRP2 8.826 14.5273 3.8359 5.0711
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 75 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 9.6894 19.5378 2.04 10.4981
G-mel GDSC2 2.8347 6.143 1.9966 17.8847
MZ-MEL-2 GDSC2 3.1394 6.2163 1.7199 10.6737
CP50-MEL-B GDSC2 3.4946 6.9481 1.6507 10.0652
MZ-MEL-7 GDSC2 3.5437 7.8519 1.239 12.4486
DJM-1 GDSC2 3.7956 6.4597 2.1282 6.2855
A-388 GDSC2 3.8145 7.2107 1.7712 8.4581
A-431 GDSC2 3.9661 7.6493 1.6688 8.7065
Hs 938.T GDSC2 4.1822 6.9195 2.1798 5.0778
LB2518-MEL GDSC2 4.3518 7.7001 1.9203 6.2783
VMRC-MELG GDSC2 4.4876 7.1702 2.2608 3.9881
COLO 783 GDSC2 4.6907 5.9813 2.8869 0.5469
GAK GDSC2 4.7076 8.1093 2.7393 8.128
MeWo GDSC2; CTRP2 4.7242 7.9679 3.8419 12.1662
HMV-II GDSC2 5.0929 10.636 1.7821 12.4813
MMAc-SF GDSC2 5.1031 7.0548 2.6484 1.1257
SH-4 GDSC2 5.1099 8.6208 2.7885 6.9372
WM278 GDSC2 5.1724 7.2849 3.475 3.0308
RPMI-7951 GDSC2; CTRP2 5.1898 8.1539 4.2139 11.2612
451Lu GDSC2 5.2455 7.1521 2.6744 0.9007
IST-MEL1 GDSC2 5.3876 7.2386 2.7025 0.6983
WM115 GDSC2; CTRP2 5.3968 5.9388 5.3634 4.4295
WM266-4 CTRP2 5.3985 5.9237 5.3684 4.4067
G-361 GDSC2; CTRP2 5.4209 8.2055 4.4086 8.1821
WM1552C GDSC2 5.426 7.3477 3.6 1.9875
M14 GDSC2 5.7497 11.6406 1.7735 11.0548
WM35 GDSC2 5.7675 9.0647 3.0198 4.4202
LB373-MEL-D GDSC2 5.8363 16.4128 -1.2648 19.0097
SK-MEL-24 GDSC2; CTRP2 5.8626 11.5025 3.1624 12.4169
CP66-MEL GDSC2 5.9145 7.3681 3.8342 0.5202
LOX-IMVI GDSC2; CTRP2 6.0082 9.7323 4.1702 7.9462
Hs 895.T CTRP2 6.054 8.15 4.9996 4.3733
CHL-1 GDSC2 6.1009 8.9539 3.2666 2.6806
COLO 679 GDSC2 6.1756 9.8743 2.8963 4.3989
WT2-iPS GDSC2; CTRP2 6.3564 9.8064 4.4167 6.2624
IPC-298 GDSC2; CTRP2 6.4422 7.5887 5.5733 1.331
IGR-37 GDSC2; CTRP2 6.4447 10.8352 3.9739 7.9544
Mel Ho GDSC2; CTRP2 6.5382 9.4806 4.7185 4.6898
Hs 940.T GDSC2; CTRP2 6.6319 11.6889 3.6956 8.7782
RVH-421 GDSC2; CTRP2 6.6712 8.3636 5.3563 1.8825
SK-MEL-1 GDSC2; CTRP2 6.6949 8.7417 5.1918 2.5054
SK-MEL-5 GDSC2; CTRP2 6.7131 8.809 5.1719 2.5599
SK-MEL-2 GDSC2; CTRP2 6.7984 7.7355 5.7138 0.4478
Hs 944.T CTRP2 6.8324 8.2967 5.4875 1.187
SK-MEL-28 GDSC2; CTRP2 6.9003 7.9355 5.681 0.4727
WM793 GDSC2; CTRP2 6.9291 9.8241 4.8314 3.6228
SK-MEL-30 GDSC2; CTRP2 6.9371 10.2292 4.6412 4.3816
K029AX CTRP2 6.9524 10.5063 4.5174 4.8628
COLO 800 GDSC2; CTRP2 6.9708 8.643 5.4118 1.3148
Hs 839.T CTRP2 7.176 8.1756 5.7106 0.2419
MDA-MB-435S CTRP2 7.2106 10.4128 4.7389 3.6023
Mel JuSo GDSC2; CTRP2 7.2644 8.8953 5.4614 0.8738
Hs 688(A).T CTRP2 7.2798 12.0378 4.0044 6.4558
HMCB CTRP2 7.5359 8.7759 5.6335 0.2584
CJM [Human melanoma] CTRP2 7.5412 18.665 0.934 17.4897
WM1799 CTRP2 7.5568 10.8463 4.7563 3.097
UACC-257 GDSC2; CTRP2 7.5893 10.8753 4.7628 3.0335
Hs 852.T CTRP2 7.5911 9.5253 5.3614 0.9335
IGR-39 CTRP2 7.6182 8.8993 5.621 0.2528
A2058 GDSC2; CTRP2 7.6514 8.6116 5.736 0.0727
UACC-62 GDSC2; CTRP2 7.666 8.7205 5.7036 0.1072
WM88 CTRP2 7.7199 15.6599 2.5514 11.5108
Hs 294T CTRP2 7.844 11.7183 4.5301 3.6142
SK-MEL-31 GDSC2; CTRP2 7.8939 9.5631 5.4852 0.4252
A101D GDSC2; CTRP2 8.0426 9.2483 5.6569 0.0946
Hs 934.T CTRP2 8.1133 14.4335 3.4236 7.5544
A-375 GDSC2; CTRP2 8.1189 13.742 3.7568 6.2499
SK-MEL-3 GDSC2; CTRP2 8.3958 9.7867 5.5979 0.1015
Hs 936.T CTRP2 8.4935 14.8168 3.4927 6.7729
COLO 829 GDSC2; CTRP2 8.7106 14.1437 3.942 4.8105
IGR-1 GDSC2; CTRP2 8.9026 16.972 2.7397 9.058
HT-144 GDSC2; CTRP2 9.3383 16.9578 3.0276 7.4371
WM983B CTRP2 9.676 15.5332 3.8755 4.0325
COLO 792 GDSC2; CTRP2 10.5978 19.8623 2.4604 7.9435
EquiPSC Line K2 GDSC2 3.4619 6.4566 1.8697 8.7877
⏷ Show the Full List of 75 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-220 GDSC2 2.9323 5.9845 2.1665 16.6279
HCE-4 GDSC2 3.5819 6.4595 1.9642 7.8644
OACM5.1 C GDSC2 4.3021 6.928 3.0023 7.6443
ESO-26 GDSC2 5.1747 7.9442 3.1627 4.7242
SK-GT-4 GDSC2 5.4357 8.3005 3.1666 4.2155
OACP4 C GDSC2 5.6935 8.2871 3.3322 2.9302
TE-12 GDSC2 6.125 9.3216 3.1168 3.3722
KYSE-50 GDSC2 6.266 8.2474 3.6461 0.9013
FLO-1 GDSC2 6.3838 10.9002 2.5511 5.8238
KYAE-1 GDSC2 6.6035 8.0358 3.8603 0.1769
ESO-51 GDSC2 7.0673 9.2389 3.6066 0.5437
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2; CTRP2 4.5162 8.6944 3.3003 14.8572
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-32 CTRP2 2.3416 6.4495 1.8859 26.2493
MHH-NB-11 GDSC2; CTRP2 2.707 4.8501 2.6453 26.5511
SK-N-MC-IXC GDSC2 2.765 3.8762 2.5072 7.0454
CHP-134 GDSC2 2.7891 5.1352 2.3734 16.0566
SiMa GDSC2; CTRP2 2.8026 5.498 2.6393 26.2118
NB69 GDSC2 2.9766 5.165 2.5608 14.3613
SJNB-10 GDSC2 3.3355 6.9461 2.1184 15.5164
IMR-5 GDSC2 3.4571 5.3941 2.9638 10.447
KP-N-RT-BM-1 GDSC2 3.7496 5.9748 2.3329 5.1228
CHP-212 GDSC2; CTRP2 3.8013 6.6774 3.3984 16.3882
LA-N-6 GDSC2 4.0267 5.8428 2.5893 2.945
KP-N-YS GDSC2 4.0609 7.6803 1.7237 8.1379
SJNB-6 GDSC2 4.1056 6.7999 2.1848 5.213
SJNB-5 GDSC2 4.3703 7.9708 1.8026 6.9456
SJNB-12 GDSC2 4.5672 7.5002 2.157 4.4408
SJNB-17 GDSC2 4.6949 7.1468 2.3963 2.8699
GOTO GDSC2 4.7246 9.1022 2.2585 10.7906
Kelly GDSC2; CTRP2 4.9277 7.3367 4.3316 9.6918
SK-N-DZ GDSC2; CTRP2 4.9316 8.344 3.8732 11.5271
SJNB-13 GDSC2 5.0383 7.3873 3.3374 4.0287
CHP-126 GDSC2; CTRP2 5.1001 7.2964 4.525 8.4786
KP-N-SI9s CTRP2 5.2215 7.2794 4.6551 7.6498
SK-N-BE(2) CTRP2 5.2881 13.4716 1.6831 19.3117
SK-N-SH GDSC2; CTRP2 5.296 9.4216 3.6977 11.4038
NB(TU)1 GDSC2 5.4094 9.6045 2.5229 7.7759
SJNB-14 GDSC2 5.4591 7.6035 3.5041 2.4158
NB1 GDSC2; CTRP2 5.71 7.7072 4.9202 5.4132
TGW GDSC2 5.7283 7.9002 3.5243 1.9467
GI-ME-N GDSC2 5.8805 12.5986 1.3997 12.6568
SK-N-AS GDSC2; CTRP2 5.9818 6.7893 5.6185 1.9146
NH-6 CTRP2 6.0368 7.3226 5.399 2.7277
SK-N-BE(2)-M17 GDSC2 6.1488 7.8642 3.7441 0.6547
SK-N-FI GDSC2; CTRP2 6.2227 7.5986 5.4104 2.3399
KP-N-YN GDSC2; CTRP2 6.4341 12.5907 3.0901 11.6096
SJNB-7 GDSC2 6.5331 7.8436 3.9012 0.1319
NH-12 GDSC2 6.6395 8.6644 3.6466 0.6536
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2; CTRP2 5.3084 8.3992 4.2088 10.9583
SNU-478 CTRP2 5.6749 8.5516 4.4709 7.3634
SNU-245 CTRP2 5.9057 12.2023 2.8491 18.099
SNU-1079 CTRP2 6.1491 11.2506 3.5281 13.9715
SNU-1196 CTRP2 6.4232 8.5091 5.1117 4.4268
HuH-28 CTRP2 6.8412 8.4718 5.4129 1.4534
SNU-869 CTRP2 8.4273 16.4834 2.6525 10.0497
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 90 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC2 2.9264 5.4852 2.3766 15.5243
HCC1599 GDSC2 3.3594 8.1347 0.9467 14.7125
CAL-148 GDSC2; CTRP2 3.9336 8.0473 2.9987 17.5488
HCC1187 GDSC2 4.1734 6.9612 2.8766 8.715
MRK-nu-1 GDSC2 4.336 7.1834 2.9029 8.1257
UACC-812 GDSC2 4.3481 7.5029 2.0125 5.7325
EFM-19 GDSC2 4.5598 6.5457 3.4015 4.6998
HCC2157 GDSC2 4.791 6.3226 3.6804 2.6207
Evsa-T GDSC2 4.8247 8.6791 2.5468 8.9371
MDA-MB-175-VII GDSC2 4.9029 7.0245 2.563 1.722
YMB-1-E GDSC2 4.9481 8.0337 2.1437 3.8457
UACC-893 GDSC2 4.9585 7.6375 2.3271 2.8393
MDA-MB-436 GDSC2 5.0647 7.5807 3.2624 4.3908
MDA-MB-157 GDSC2; CTRP2 5.3268 8.5172 4.1687 9.3875
MDA-MB-330 GDSC2 5.412 7.4713 3.5362 2.3247
BT-483 GDSC2 5.6333 8.263 2.4086 1.6257
MDA-MB-415 GDSC2 5.7218 10.5857 2.266 8.5272
HCC2218 GDSC2; CTRP2 6.058 9.7027 4.2266 7.6134
HCC1500 GDSC2; CTRP2 6.1001 10.1208 4.0525 8.2626
MFM-223 GDSC2 6.1289 7.7687 3.7722 0.5792
BT-20 GDSC2; CTRP2 6.1911 8.1912 5.0907 3.7345
JIMT-1 GDSC2; CTRP2 6.3033 8.1469 5.2003 3.642
CAL-51 GDSC2; CTRP2 6.345 8.8468 4.8852 4.3223
CAL-85-1 GDSC2; CTRP2 6.3869 11.8402 3.4267 10.3255
HCC70 GDSC2 6.4118 8.0498 3.7829 0.4001
COLO 824 GDSC2 6.6096 8.6593 3.636 0.7025
MCF-7 GDSC2; CTRP2 6.6487 10.2474 4.4228 6.7809
HMC-1-8 CTRP2 6.6537 8.3342 5.3588 1.896
OCUB-M GDSC2 6.6803 9.0276 3.5243 1.0164
HCC1954 GDSC2; CTRP2 6.7578 9.0261 5.0981 3.3047
SK-BR-3 CTRP2 6.7588 32.2164 -6.4512 33.4815
HCC38 GDSC2; CTRP2 6.9106 9.1699 5.1311 2.4534
CAMA-1 GDSC2; CTRP2 6.9718 9.0382 5.2317 2.3499
HCC1143 GDSC2; CTRP2 6.995 10.6841 4.4611 5.0284
MDA-MB-468 GDSC2; CTRP2 7.0028 12.8586 3.3993 9.3557
AU565 GDSC2; CTRP2 7.0701 10.2508 4.7224 3.861
Hs 578Bst CTRP2 7.1376 9.7151 5.0204 2.5951
MDA-MB-231 GDSC2; CTRP2 7.142 9.6893 5.0353 2.5322
MDA-MB-361 GDSC2; CTRP2 7.18 14.0939 2.9224 10.9638
EFM-192A GDSC2; CTRP2 7.3184 11.3978 4.3406 5.0421
T-47D GDSC2; CTRP2 7.3521 11.7945 4.1728 5.6685
HCC1569 GDSC2 7.5406 10.0972 3.4794 0.6473
BT-474 GDSC2; CTRP2 7.5988 11.2877 4.5772 3.7324
HCC1395 GDSC2; CTRP2 7.6226 9.7133 5.2983 1.1049
MDA-MB-453 GDSC2; CTRP2 7.6234 9.8992 5.2194 1.3593
HCC1806 GDSC2; CTRP2 7.6693 9.4545 5.428 0.8128
HCC1428 GDSC2; CTRP2 7.7477 9.2846 5.5296 0.3912
ZR-75-1 CTRP2 7.7532 9.0519 5.6185 0.2128
Hs 578T GDSC2; CTRP2 7.8672 15.6105 2.6822 10.7817
BT-549 GDSC2; CTRP2 7.8855 11.5384 4.6379 3.1615
HCC1419 GDSC2; CTRP2 7.8958 11.0106 4.8817 2.264
HCC1937 GDSC2; CTRP2 8.0213 10.0156 5.3653 0.6488
HDQ-P1 GDSC2; CTRP2 8.1353 9.7713 5.5062 0.3436
CAL-120 GDSC2; CTRP2 8.2389 9.488 5.6444 0.0934
ZR-75-30 GDSC2; CTRP2 8.2559 13.3482 4.0298 5.0209
HCC202 CTRP2 8.3607 10.5424 5.3091 0.6126
BT 271 CTRP2 2.1182 9.2173 0.6132 31.0628
BT 286 CTRP2 2.524 7.6738 1.6606 26.4771
BT 131 CTRP2 2.6364 9.0796 1.2115 27.6516
BT 239 CTRP2 4.1094 8.3764 3.0355 16.9412
BT 330 CTRP2 4.3476 13.3603 0.8913 24.1304
BT 504 CTRP2 4.6609 13.3924 1.1621 22.5138
BT 340 CTRP2 5.237 12.2132 2.2638 17.2814
BT 172 CTRP2 5.2906 11.8033 2.5149 16.1973
BT147 CTRP2 5.3803 17.2166 -0.1043 24.7371
BT 145 CTRP2 5.7434 7.805 4.9021 5.4158
BT 482 CTRP2 5.8879 12.0141 2.9281 13.314
BT 416 CTRP2 5.9408 7.9161 5.0209 4.5062
BT 428 CTRP2 6.0305 9.7312 4.1894 7.8223
BT 112 CTRP2 6.0395 7.1085 5.5083 2.2631
BT164 CTRP2 6.0872 6.944 5.6297 1.6621
BT 245 CTRP2 6.3323 16.3249 1.1421 19.0266
BT 216 CTRP2 6.5636 16.638 1.1738 18.4766
BT 248 CTRP2 6.5926 9.6808 4.6604 4.8413
BT 320 CTRP2 6.7795 9.8562 4.711 4.3352
BT 440 CTRP2 6.8003 16.0657 1.649 16.407
BT 232 CTRP2 6.8865 15.0706 2.2124 14.2041
BT 444 CTRP2 6.9365 8.8611 5.2918 1.7994
BT 179 CTRP2 7.0292 8.48 5.5163 0.8928
BT 159 CTRP2 7.3044 12.9789 3.5629 8.2041
BT 139 CTRP2 7.3866 11.4459 4.3637 4.8534
BT 228 CTRP2 7.4338 13.1083 3.5927 7.8829
BT 224 CTRP2 7.508 9.069 5.5081 0.5677
BT 231 CTRP2 8.3741 14.667 3.4858 6.9571
BT 187 CTRP2 8.5978 13.6774 4.0875 4.4004
BT 333 CTRP2 8.6921 16.7079 2.7251 9.4017
BT 422 CTRP2 8.8566 25.1771 -1.2914 21.5147
BT 498 CTRP2 10.1631 29.2533 -2.3321 21.9396
BT 359 CTRP2 10.2377 21.9533 1.2545 12.3765
BT 328 CTRP2 12.4588 25.5117 0.9948 10.5136
⏷ Show the Full List of 90 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 6.3572 7.7804 5.4213 2.0738
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D-502MG GDSC2 2.7137 8.7712 0.0752 21.4822
H4 GDSC2 3.0109 7.1945 1.6868 18.9148
MOG-G-UVW GDSC2 3.7205 6.2323 2.1841 6.1236
D-423MG GDSC2 3.7863 6.9181 1.8947 7.7637
D-245MG GDSC2 3.8452 6.3872 2.2005 5.715
D-336MG GDSC2 4.0322 8.44 1.328 10.606
Daoy GDSC2; CTRP2 4.051 7.2467 3.4537 15.4716
D-542MG GDSC2 4.0981 7.8686 1.6585 8.4459
D283 Med GDSC2; CTRP2 4.2061 6.8888 3.7577 13.8768
LNZTA3WT4 GDSC2 4.2212 12.269 -0.426 19.3954
KNS-81-FD GDSC2 4.4009 7.5296 2.0351 5.4869
D-247MG GDSC2 4.5648 9.9912 0.9578 11.4555
KS-1 [Human Krukenberg tumour] GDSC2 4.6891 10.8754 1.3459 15.7235
Onda 10 GDSC2 4.7088 7.5984 2.1992 3.9422
Onda 11 GDSC2 4.8854 8.1508 2.0527 4.4606
GB-1 GDSC2; CTRP2 5.236 8.2379 4.2179 9.3944
M059J GDSC2 5.4473 8.0575 3.288 3.5498
KNS-42 GDSC2; CTRP2 5.4788 10.6428 3.2584 12.8165
D-392MG GDSC2 5.5893 9.7089 2.5975 7.0062
KNS-81 CTRP2 5.6082 9.8217 3.1078 9.6579
NMC-G1 GDSC2; CTRP2 5.6816 6.3199 5.5499 3.4369
D-566MG GDSC2 5.7411 7.5099 2.7442 0.3906
PFSK-1 GDSC2 5.7682 10.9279 2.1328 9.1414
CAS-1 GDSC2 5.7806 7.3588 3.7784 0.8077
MOG-G-CCM GDSC2 5.8318 8.3988 2.4459 1.2935
ONS-76 GDSC2; CTRP2 5.9137 9.1029 4.4049 8.4542
SF539 GDSC2; CTRP2 6.0086 10.1006 3.9864 8.7157
Hs 683 GDSC2; CTRP2 6.0196 9.226 4.4329 6.8215
YKG-1 GDSC2; CTRP2 6.1331 7.2115 5.533 1.9844
GI-1 GDSC2 6.1426 9.1774 3.1911 2.9859
A-172 GDSC2; CTRP2 6.1435 14.3214 1.9882 16.435
SNU-626 CTRP2 6.2134 8.2951 5.0566 5.2312
D-263MG GDSC2 6.2697 7.4717 3.935 0.1399
KNS-60 CTRP2 6.2985 7.2822 4.7207 0.2397
KINGS-1 GDSC2 6.3052 10.9533 2.4773 6.333
SNU-738 CTRP2 6.3276 7.764 5.4077 2.9679
LN-405 GDSC2 6.4833 7.7516 3.915 0.123
AM-38 GDSC2; CTRP2 6.5015 10.209 4.3297 6.371
SNU-466 CTRP2 6.5506 8.2639 5.3229 2.1836
SK-MG-1 GDSC2 6.5919 8.47 3.6999 0.5293
SF268 GDSC2; CTRP2 6.846 11.3693 4.0169 7.0884
GMS-10 CTRP2 6.8485 8.0356 5.6122 0.7325
M059K CTRP2 6.8906 11.0702 4.1971 6.2734
U-87MG ATCC GDSC2; CTRP2 6.9524 9.9474 4.788 4.4531
SF126 GDSC2; CTRP2 7.0175 8.984 5.2846 1.7323
CCF-STTG1 CTRP2 7.0344 9.1799 5.2048 2.0138
DBTRG-05MG GDSC2; CTRP2 7.0578 9.3435 5.1435 2.2194
U-251MG GDSC2; CTRP2 7.1226 11.1023 4.3479 5.2976
TM-31 CTRP2 7.2125 9.1267 5.3334 1.349
LN-18 GDSC2; CTRP2 7.2206 8.2884 5.6864 0.2757
42-MG-BA GDSC2; CTRP2 7.2395 11.1124 4.4239 4.8197
SNU-1105 CTRP2 7.2768 8.5289 5.6175 0.5636
LN-229 GDSC2; CTRP2 7.2781 9.6971 5.115 2.0701
KG-1-C CTRP2 7.3288 8.7635 5.5477 0.5695
SNU-489 CTRP2 7.347 8.5288 5.6482 0.4154
SW1088 GDSC2; CTRP2 7.4381 11.2447 4.4939 4.2662
KALS-1 GDSC2; CTRP2 7.5691 12.6756 3.8974 6.4592
U-118MG GDSC2; CTRP2 7.5972 12.3663 4.0651 5.7496
DK-MG GDSC2; CTRP2 7.6323 8.9573 5.6051 0.2788
Becker GDSC2; CTRP2 7.8343 12.4023 4.2046 4.8796
SF295 GDSC2; CTRP2 7.8636 9.1416 5.6287 0.1661
GOS-3 CTRP2 7.9711 12.8408 4.0864 5.1624
8-MG-BA GDSC2; CTRP2 8.01 10.07 5.3386 0.7239
GaMG GDSC2; CTRP2 8.1245 9.5732 5.5735 0.1835
YH-13 GDSC2; CTRP2 8.7654 14.199 3.9497 4.72
SNU-201 CTRP2 9.2528 18.3358 2.323 13.0276
SW1783 GDSC2; CTRP2 9.28 19.4038 1.8309 11.7738
T98G GDSC2; CTRP2 9.3954 18.6513 2.2673 10.0972
SNB-75 GDSC2; CTRP2 9.4677 17.6033 2.8079 8.0726
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC1TKB GDSC2 4.4236 5.9553 2.7704 1.3098
TGBC24TKB GDSC2 6.1793 8.3934 3.5467 1.3506
ETK-1 GDSC2 6.5485 9.0503 3.4549 1.3741
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-1 CTRP2 0.1439 5.0431 -0.1518 40.0797
JHUEM-2 CTRP2 2.436 4.6808 2.3779 26.0314
HEC-151 CTRP2 3.8713 7.2249 3.2713 16.6692
MFE-296 GDSC2; CTRP2 5.1749 8.388 4.0875 10.0729
JHUEM-7 CTRP2 5.9798 8.5897 4.7175 5.7032
ESS-1 GDSC2; CTRP2 6.2255 9.105 4.6622 5.4695
MFE-319 GDSC2; CTRP2 6.3084 8.4838 5.0371 3.7512
MFE-280 GDSC2 6.3527 9.7198 3.0685 3.2907
KLE GDSC2; CTRP2 6.3767 9.4307 4.6196 5.3773
HEC-251 CTRP2 6.7616 9.0918 5.069 3.1201
HEC-59 CTRP2 6.7935 10.2461 4.5304 5.0552
HEC-1-B CTRP2 6.8272 9.769 4.7872 5.3848
HEC-6 CTRP2 6.8945 11.2296 4.1217 7.0619
RL95-2 GDSC2; CTRP2 6.8971 9.6679 4.8846 4.0866
JHUEM-3 CTRP2 7.0509 9.6402 5.0001 2.7844
EFE-184 CTRP2 7.0734 10.452 4.6281 4.2355
HEC-50B CTRP2 7.25 9.5156 5.1808 1.8582
HEC-108 CTRP2 7.3289 9.3821 5.2854 1.4036
HEC-1-A CTRP2 7.4917 14.1534 3.1237 9.6609
HEC-265 CTRP2 7.5516 8.6351 5.6912 0.151
AN3-CA GDSC2; CTRP2 8.1005 15.4042 2.9475 9.4137
EN GDSC2; CTRP2 8.2858 9.8424 5.5385 0.1954
Ishikawa (Heraklio) 02 ER- CTRP2 7.7889 8.573 5.7957 0.0178
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW156 GDSC2 3.1772 6.2439 1.7387 10.4406
KTCTL-140 GDSC2 3.3501 5.6939 2.1594 7.2781
LB2241-RCC GDSC2 3.6001 6.3423 2.0368 7.3596
KTCTL-21 GDSC2 3.6055 7.2211 1.6033 10.0518
CAL-54 GDSC2; CTRP2 3.952 10.1689 2.0556 21.1009
BB65-RCC GDSC2 3.9913 9.4344 0.8041 13.7614
SW13 GDSC2 4.3244 7.4708 2.7495 9.0352
LB996-RCC GDSC2 4.4473 7.4011 2.8855 7.9365
KTCTL-1M GDSC2 4.5216 7.9162 1.9312 5.8563
HA7-RCC GDSC2 4.7268 8.346 2.6365 8.6646
KTCTL-13 GDSC2 4.7288 8.8139 1.6413 7.1372
KTCTL-26A GDSC2 5.1121 8.9622 1.8173 5.3855
LB1047-RCC GDSC2 5.3342 8.1855 2.2916 2.5037
UO-31 GDSC2; CTRP2 5.4962 10.0767 3.555 11.5589
TK-10 GDSC2 5.498 8.5985 3.0663 4.6418
NCC021 GDSC2 5.5989 7.4934 2.6941 0.596
TUHR14TKB CTRP2 5.6805 9.3742 4.0673 9.039
NCC010 GDSC2 5.6884 8.3785 3.2876 3.163
A-498 GDSC2 5.7112 9.4496 2.8029 5.6684
KTCTL-195 GDSC2 5.8105 9.9558 2.6281 6.4205
786-O GDSC2; CTRP2 5.9309 12.005 2.969 13.0638
769-P GDSC2; CTRP2 6.2866 9.0228 4.7519 5.895
RXF 393L GDSC2 6.5233 9.1466 3.4035 1.5989
BFTC-909 GDSC2; CTRP2 6.751 10.3617 4.4426 6.4866
SN12C GDSC2 6.8363 8.457 3.7986 0.2189
OS-RC-2 GDSC2; CTRP2 7.051 10.867 4.4118 6.0829
A-704 GDSC2 7.0654 9.1691 3.6314 0.4837
TUHR10TKB CTRP2 7.2655 8.7082 5.5401 0.633
KMRC-2 CTRP2 7.3196 14.0485 3.049 10.2333
KMRC-1 GDSC2; CTRP2 7.4951 9.6213 5.2712 1.2995
RCC10RGB GDSC2; CTRP2 7.7909 9.2946 5.5439 0.3421
Caki-2 CTRP2 7.9265 12.1038 4.4026 4.0004
KMRC-20 GDSC2; CTRP2 8.1162 13.209 4.0064 6.2338
TUHR4TKB CTRP2 8.1899 9.6716 5.5631 0.2492
VMRC-RCZ GDSC2; CTRP2 8.2841 9.8462 5.5365 0.1987
SNU-1272 CTRP2 8.4147 9.7073 5.6314 0.0691
KMRC-3 CTRP2 8.6781 10.3926 5.4903 0.1748
ACHN GDSC2; CTRP2 8.7202 13.7518 4.1263 4.1225
VMRC-RCW GDSC2; CTRP2 8.7605 10.4431 5.5026 0.1449
Caki-1 GDSC2; CTRP2 11.3017 19.0057 3.243 4.6353
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 59 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW48 GDSC2; CTRP2 2.6567 5.6204 2.4539 27.444
SW1463 GDSC2; CTRP2 2.6946 7.9851 1.7223 25.7544
LS513 GDSC2; CTRP2 2.8392 6.6861 2.3523 27.1794
CCK-81 GDSC2; CTRP2 3.2489 7.4878 2.5062 21.3118
GP5d GDSC2 3.8063 9.0069 1.537 17.1309
LoVo GDSC2; CTRP2 4.1209 8.3091 3.0771 16.7484
LS180 GDSC2; CTRP2 4.3533 8.113 3.4012 14.8688
SNU-283 GDSC2 4.3636 8.9681 1.3129 9.8829
SK-CO-1 GDSC2; CTRP2 4.6001 9.1186 3.1841 17.7899
HCT 15 GDSC2; CTRP2 4.6202 8.219 3.623 13.3052
HCC2998 GDSC2 4.7792 9.154 2.2756 10.5296
SNU-81 GDSC2; CTRP2 4.7805 6.9723 4.3347 10.0697
C2BBe1 GDSC2; CTRP2 4.8154 11.669 2.152 18.6495
SNU-175 GDSC2; CTRP2 4.8203 8.8504 3.5252 15.5643
HT-55 GDSC2; CTRP2 5.1807 9.5539 3.5265 12.3669
NCI-H508 GDSC2; CTRP2 5.246 12.601 2.0791 17.9583
CL-11 GDSC2; CTRP2 5.3716 8.6867 4.1278 9.4552
T84 GDSC2; CTRP2 5.4758 9.2224 3.9598 9.923
CW-2 GDSC2; CTRP2 5.65 11.3247 3.0688 13.2305
NCI-H747 GDSC2; CTRP2 5.658 11.1366 3.1695 12.8041
LS123 GDSC2; CTRP2 5.7719 7.7055 4.9771 5.0415
LS1034 GDSC2; CTRP2 5.7792 10.0494 3.8168 9.8814
DiFi GDSC2 5.8192 10.5788 2.3362 7.9362
SW626 GDSC2 5.8882 10.8885 2.2345 8.3649
SNU-407 GDSC2; CTRP2 5.9115 9.054 4.4275 7.0571
SNU-61 GDSC2; CTRP2 5.9147 9.4168 4.249 7.7999
SNU-1040 GDSC2 5.9615 7.6656 3.7389 0.8037
COLO 320HSR GDSC2 6.0027 8.7837 3.2871 2.7044
SNU-C1 GDSC2; CTRP2 6.1918 9.6964 4.3398 6.8847
SW1116 GDSC2 6.2417 13.341 1.2948 12.3773
COLO201 CTRP2 6.3397 7.8223 5.3879 2.2389
GP2d CTRP2 6.4523 11.8791 3.4596 10.0705
SW837 GDSC2 6.5374 11.3334 2.4454 6.0901
LS411N GDSC2; CTRP2 6.5737 8.1125 5.4112 2.1197
CaR-1 GDSC2 6.6789 8.162 3.8439 0.184
COLO 320 CTRP2 6.6801 11.0676 4.0409 7.2661
SNU-C5 GDSC2; CTRP2 6.6889 12.2976 3.4374 9.7388
HT115 GDSC2; CTRP2 6.7827 9.6501 4.8136 3.9104
SNU-1033 CTRP2 6.8842 12.9224 3.2778 10.0484
RCM-1 [Human ESC] GDSC2; CTRP2 6.901 8.3308 5.5115 1.0296
SW948 GDSC2; CTRP2 7.0058 15.9925 1.8471 15.3291
SNU-C2B GDSC2 7.1548 12.6049 2.2354 6.1607
SNU-C4 CTRP2 7.1586 9.6643 5.0573 2.4273
RKO GDSC2; CTRP2 7.2318 9.461 5.1948 1.8265
DLD-1 CTRP2 7.2615 8.2858 5.7044 0.3003
SNU-503 CTRP2 7.3638 12.6986 3.7425 7.3872
OUMS-23 CTRP2 7.4115 8.3022 5.7565 0.1242
HT-29 GDSC2; CTRP2 7.5335 8.8467 5.6059 0.3167
SW620 GDSC2; CTRP2 7.6408 9.4997 5.3961 0.7954
HCC-56 CTRP2 7.6546 8.8729 5.6451 0.1971
HCT 8 CTRP2 7.7767 9.1413 5.5951 0.2469
MDST8 GDSC2; CTRP2 7.8474 11.9191 4.4391 3.9568
NCI-H716 GDSC2; CTRP2 7.8729 13.6648 3.6293 7.0881
COLO 678 GDSC2; CTRP2 7.9401 14.1378 3.4478 7.7056
SNU-C2A CTRP2 8.0309 10.4382 5.1991 1.5037
SW1417 GDSC2; CTRP2 8.0811 13.3319 3.9261 5.6419
HCT 116 GDSC2; CTRP2 8.1401 9.6152 5.5644 0.193
KM12 GDSC2; CTRP2 8.6293 9.9814 5.6133 0.061
COLO205 GDSC2; CTRP2 9.8605 17.91 2.9098 8.3893
⏷ Show the Full List of 59 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 6.116 7.9052 3.7137 0.7781
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-5 CTRP2 3.3211 7.1286 2.719 20.3125
SNU-878 CTRP2 5.6557 9.6227 3.9219 13.1802
Hep-G2/C3A GDSC2 5.7972 8.9966 3.0697 4.1106
SNU-886 CTRP2 5.9482 8.0154 3.3724 0.9343
SNU-182 CTRP2 5.9839 7.6371 5.197 3.6803
HLE GDSC2 6.0067 8.4304 3.4437 1.9764
SNU-761 CTRP2 6.1279 9.9607 3.4202 6.7982
JHH-7 GDSC2 6.6046 8.264 3.7803 0.3274
Hep-G2 CTRP2 6.6712 10.7782 4.1774 6.7148
Li-7 CTRP2 6.6982 8.9805 5.079 4.0301
SNU-449 GDSC2; CTRP2 6.71 10.7843 4.2037 6.541
JHH-6 GDSC2; CTRP2 6.9374 8.2796 5.554 0.8485
Huh-7 GDSC2 6.9518 8.5934 3.7931 0.1987
Hep 3B2.1-7 GDSC2; CTRP2 7.0143 9.7854 4.9074 3.7851
PLC/PRF/5 CTRP2 7.0869 10.542 4.5939 4.3537
SNU-398 GDSC2; CTRP2 7.3718 9.3027 5.3432 1.168
SNU-475 CTRP2 7.6244 12.678 3.9341 6.2333
HuH-1 GDSC2; CTRP2 7.6647 9.1772 5.5353 0.4162
SK-HEP-1 GDSC2; CTRP2 7.7826 9.1516 5.5937 0.2475
JHH-4 GDSC2; CTRP2 8.1779 10.1488 5.382 0.5297
SNU-387 GDSC2; CTRP2 8.3193 10.007 5.4924 0.2581
JHH-2 GDSC2; CTRP2 8.3557 9.9881 5.5131 0.2158
SNU-423 GDSC2; CTRP2 8.5728 13.756 4.0365 4.6181
JHH-1 GDSC2; CTRP2 9.1972 15.6034 3.5668 5.634
HLF CTRP2 9.7549 17.7844 2.903 7.382
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 219 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H209 GDSC2; CTRP2 -0.1523 4.2103 -0.4228 45.0262
COR-L51 CTRP2 0.2078 6.3852 -0.4215 40.3941
DV-90 CTRP2 0.4895 6.122 -0.0393 38.4378
NCI-H748 GDSC2 1.1668 4.0655 0.732 23.9521
Lu-134-A GDSC2 1.5324 5.0927 0.7084 22.5085
COR-L32 GDSC2 1.7563 5.4764 0.7674 21.2686
COR-L279 GDSC2 2.015 4.2348 1.5732 15.5702
COLO 668 GDSC2; CTRP2 2.22 4.772 2.1367 25.7607
NCI-H524 GDSC2 2.4496 6.3384 1.5163 21.7915
SBC-3 GDSC2 2.7415 6.1918 1.8798 18.8385
DMS 79 GDSC2 3.0164 5.7089 2.374 15.211
NCI-H1876 GDSC2 3.0257 6.0217 2.2448 15.875
NCI-H82 GDSC2 3.1114 6.1073 2.2925 15.3166
NCI-H146 GDSC2 3.1693 6.4477 1.6301 11.1435
NCI-H1437 GDSC2 3.1903 4.6828 2.5289 5.4171
NCI-H1963 GDSC2 3.231 6.5792 2.192 15.458
HCC1588 CTRP2 3.4166 7.07 2.8432 19.5742
NCI-H2141 GDSC2; CTRP2 3.4337 7.0491 2.8692 19.428
NCI-H847 GDSC2 3.5017 6.1972 2.0312 7.661
NCI-H1694 GDSC2; CTRP2 3.524 5.4771 3.4253 17.129
EMC-BAC-2 GDSC2 3.6661 7.6698 2.0743 14.7191
NCI-H290 GDSC2 3.7264 6.4224 2.0945 6.6692
NCI-H2171 GDSC2 3.7302 6.2117 2.2016 5.9902
NCI-H211 GDSC2; CTRP2 3.7309 6.4324 3.4039 16.5739
NCI-H810 GDSC2; CTRP2 3.7804 7.2955 3.147 17.3965
COR-L303 GDSC2 3.8115 7.6348 1.5587 9.7763
Lu-99 CTRP2 3.8405 9.2924 2.3508 27.1436
NCI-H1155 GDSC2; CTRP2 3.8474 6.2012 3.6021 18.3375
NCI-H2081 GDSC2; CTRP2 3.8807 10.0278 2.0515 21.299
LB647-SCLC GDSC2 3.9133 6.7469 2.0738 6.3369
DMS 53 GDSC2; CTRP2 3.938 8.5435 2.7865 18.3596
NCI-H1105 GDSC2; CTRP2 3.9384 7.8923 3.0697 17.2606
HCC33 GDSC2 3.9647 5.8066 2.5657 3.2098
SBC-1 GDSC2 3.978 5.8682 2.5454 3.3045
NCI-H1648 GDSC2 4.0476 9.6227 0.754 13.8935
SBC-5 GDSC2; CTRP2 4.1225 6.2185 3.897 13.5992
PaCa-3 GDSC2 4.2234 6.7094 2.3077 4.2241
NCI-H510A GDSC2 4.2243 6.3047 2.4987 3.0983
NCI-H1770 GDSC2 4.2355 8.313 1.5408 8.8299
DMS 273 GDSC2; CTRP2 4.2824 10.1179 2.4018 18.9695
Ms-1 GDSC2 4.3076 6.7496 3.0961 7.0909
NCI-H1781 GDSC2 4.3506 8.8381 2.0877 12.6947
NCI-H740 GDSC2 4.4799 9.8566 0.9622 11.6325
NCI-H69 GDSC2; CTRP2 4.4856 9.1055 3.0783 15.8197
IST-SL1 GDSC2 4.6719 8.0682 1.9575 5.4019
COR-L95 GDSC2; CTRP2 4.7354 7.9652 3.8544 12.0879
NCI-H1836 GDSC2 4.765 6.4278 2.7432 1.0516
NCI-H1385 CTRP2 4.7864 8.7254 3.5515 13.1838
NCI-H2227 GDSC2 4.8335 12.5934 0.6044 18.8512
CPC-N GDSC2 4.897 8.3339 2.7727 7.4962
NCI-H835 GDSC2 4.9086 9.6029 1.3851 8.2487
NCI-H64 GDSC2 4.9635 6.4079 2.8398 0.5218
NCI-H1184 CTRP2 4.9639 8.822 3.6772 12.2486
LC-2/ad GDSC2 4.9795 8.2123 2.0811 4.1396
NCI-H2347 GDSC2 4.9871 8.8236 1.804 5.6887
Lu-139 GDSC2 5.0066 9.1453 2.4543 9.032
NCI-H1436 GDSC2 5.0376 6.8398 2.7043 0.9583
NCI-H526 GDSC2; CTRP2 5.0698 7.1057 4.5789 8.3422
NCI-H1092 GDSC2; CTRP2 5.0888 7.7089 4.325 9.3111
COR-L311 GDSC2 5.0995 7.4794 3.3348 3.9241
NCI-H2066 GDSC2 5.107 6.9354 2.6978 0.9242
NCI-H2106 CTRP2 5.1442 7.9231 4.2793 12.7589
NCI-H522 GDSC2; CTRP2 5.1479 9.3548 3.5934 12.166
HCC44 GDSC2; CTRP2 5.1699 9.1433 3.717 11.6078
NCI-H2804 GDSC2 5.1741 9.8951 2.2097 9.9995
NCI-H2795 GDSC2 5.1752 11.2528 1.5393 13.5442
NCI-H1581 GDSC2; CTRP2 5.1892 7.874 4.3463 10.6233
NCI-H2731 GDSC2 5.2318 7.9784 3.1851 4.4909
Lu-135 GDSC2 5.2339 8.3647 3.0008 5.5001
NCI-H1395 CTRP2 5.2494 14.4991 1.1375 21.271
COR-L321 GDSC2 5.308 7.1943 2.6854 0.8126
COR-L88 GDSC2; CTRP2 5.33 13.0084 1.9504 18.2527
Lu-165 GDSC2 5.3859 7.2039 3.6413 1.8415
DMS 454 CTRP2 5.3945 8.7266 4.1295 9.3971
NCI-H1048 GDSC2 5.4124 7.4782 3.5333 2.3385
Calu-3 GDSC2; CTRP2 5.4906 9.0008 4.0827 9.3795
NCI-H3255 GDSC2 5.5198 9.3705 2.7127 6.5168
NCI-H1703 GDSC2; CTRP2 5.5509 11.1873 3.051 13.5091
NCI-H446 GDSC2; CTRP2 5.5915 9.714 3.8197 10.2581
NCI-H1693 GDSC2; CTRP2 5.5936 6.5156 5.3752 3.8244
NCI-H520 GDSC2; CTRP2 5.6366 9.8011 3.8163 10.178
A-427 GDSC2 5.6497 11.5086 1.7661 11.3068
NCI-H1341 GDSC2; CTRP2 5.652 7.4309 5.002 5.2025
EMC-BAC-1 GDSC2 5.6697 8.0783 2.4995 1.2215
NCI-H322M GDSC2 5.6915 9.2589 2.8802 5.2908
NCI-H2722 GDSC2 5.694 7.9523 3.4824 2.1899
COR-L23 GDSC2 5.7143 10.6915 2.2096 8.843
NCI-H1993 GDSC2 5.7361 8.3639 3.3224 2.9158
NCI-H345 GDSC2 5.7445 6.5654 4.0588 0.0748
NCI-H1975 GDSC2 5.7525 14.0526 0.5912 16.6996
NCI-H1573 GDSC2 5.7659 7.647 2.7042 0.481
Lu-99A GDSC2 5.7848 9.436 2.857 5.2484
NCI-H2196 GDSC2; CTRP2 5.8199 8.6802 4.535 6.7914
NCI-H3122 GDSC2 5.8505 9.41 2.9109 4.8506
NCI-H1688 GDSC2 5.8692 7.6473 2.7438 0.3415
NCI-H513 GDSC2 5.8881 13.1846 1.1184 13.9971
NCI-H1373 CTRP2 5.9136 6.753 5.576 2.2368
SW1271 GDSC2; CTRP2 5.9238 9.1683 3.6614 5.5449
ABC-1 GDSC2 5.9697 8.346 3.4604 1.9444
HCC4006 CTRP2 5.9733 7.0899 5.4613 2.5918
NCI-H720 GDSC2 5.976 7.9463 3.6321 1.2003
NCI-H2228 GDSC2; CTRP2 5.9893 11.5867 2.5235 11.286
NCI-H2087 GDSC2; CTRP2 6.0088 8.2387 4.9175 4.8059
DMS 114 GDSC2; CTRP2 6.0368 9.295 4.4127 6.8728
NCI-H2369 GDSC2 6.0677 7.6105 3.8066 0.5119
NCI-H1734 GDSC2; CTRP2 6.1055 9.5473 4.3436 7.031
NCI-H2373 GDSC2 6.1379 8.8483 3.3329 2.3234
LCLC-97TM1 GDSC2 6.138 10.1982 2.7241 5.3408
NCI-H838 GDSC2; CTRP2 6.1421 7.3992 5.4466 2.3303
Calu-6 GDSC2; CTRP2 6.2259 10.5373 3.9473 8.465
NCI-H2869 GDSC2 6.2691 8.8601 3.3965 1.887
NCI-H2444 GDSC2; CTRP2 6.275 7.2815 4.7116 0.2583
SW1573 GDSC2 6.2755 11.7367 2.089 8.3857
NCI-H2803 GDSC2 6.2968 11.3792 2.2721 7.405
NCI-H2461 GDSC2 6.3003 12.1887 1.8901 9.3537
SK-MES-1 GDSC2; CTRP2 6.3043 8.1952 5.1772 3.1735
RERF-LC-A1 CTRP2 6.3615 9.7086 4.4694 6.0327
RERF-LC-KJ GDSC2 6.3741 7.8766 3.8312 0.3027
NCI-H1650 GDSC2; CTRP2 6.3948 9.4601 4.6191 5.3481
NCI-H1793 GDSC2; CTRP2 6.4017 10.3007 4.2062 7.0621
NCI-H650 GDSC2; CTRP2 6.471 12.898 2.9663 14.1012
NCI-H292 GDSC2; CTRP2 6.5007 8.7132 5.0685 3.301
IST-SL2 GDSC2 6.5073 9.025 3.4456 1.4467
NCI-H889 CTRP2 6.5357 9.4202 4.7464 4.578
NCI-H596 GDSC2 6.5525 8.7473 3.5774 0.9275
NCI-H1944 GDSC2; CTRP2 6.5742 13.8928 2.5525 13.4786
NCI-H2122 GDSC2; CTRP2 6.5934 8.4911 5.2429 2.4454
NCI-H226 GDSC2; CTRP2 6.6263 8.2272 4.499 0.6732
NCI-H1666 GDSC2; CTRP2 6.6284 12.6429 3.2183 10.7378
NCI-H250 GDSC2 6.6314 8.6565 3.6462 0.6595
NCI-H2810 GDSC2 6.6528 8.9217 3.5535 0.9371
NCI-H2286 CTRP2 6.7184 8.4718 5.3359 1.9005
EBC-1 GDSC2; CTRP2 6.7208 9.8158 4.6884 4.5193
UMC-11 GDSC2 6.7217 8.566 3.7164 0.4268
NCI-H2405 GDSC2; CTRP2 6.7328 8.4755 5.3435 2.1912
RERF-LC-Ad2 CTRP2 6.7348 8.966 5.1112 2.7732
LC-1/sq GDSC2 6.7477 13.5608 1.5341 10.2762
NCI-H2595 GDSC2 6.7641 8.9436 3.593 0.7402
HCC1195 CTRP2 6.7712 8.3269 5.437 1.4444
NCI-H661 GDSC2; CTRP2 6.7935 8.5111 5.3654 1.691
NCI-H2029 GDSC2; CTRP2 6.8898 10.429 4.5105 4.987
NCI-H2135 GDSC2 6.9343 8.57 3.7949 0.2002
NCI-H23 GDSC2; CTRP2 6.9713 12.8878 3.3612 9.563
SK-LU-1 GDSC2; CTRP2 6.9975 9.0411 5.2462 1.9002
NCI-H841 GDSC2; CTRP2 7.0462 10.9593 4.3635 5.3487
HCC366 GDSC2; CTRP2 7.0726 9.5933 5.0362 3.0943
NCI-H1651 GDSC2; CTRP2 7.116 11.7025 4.0511 6.5165
PC-14 GDSC2; CTRP2 7.1172 9.0488 4.3944 0.68
LK-2 GDSC2 7.1196 15.1229 1.0374 11.909
RERF-LC-Sq1 GDSC2 7.1639 14.5326 1.3463 10.4136
BEN GDSC2; CTRP2 7.174 8.083 5.7444 0.206
NCI-H2170 GDSC2; CTRP2 7.2165 11.8495 4.0512 6.362
HCC1438 CTRP2 7.226 9.5283 5.1609 1.958
VMRC-LCD GDSC2; CTRP2 7.2519 11.6344 4.1805 5.7843
NCI-H196 GDSC2; CTRP2 7.2761 9.3195 5.2836 1.4612
NCI-H322 CTRP2 7.2973 12.8954 3.5987 8.071
LK2 CTRP2 7.3059 8.2068 5.7509 0.1231
NCI-H2818 GDSC2 7.3126 9.0153 3.7766 0.1475
NCI-H1792 GDSC2; CTRP2 7.3179 9.4968 5.2285 1.6147
RERF-LC-Ad1 CTRP2 7.329 8.1975 5.7628 0.1002
LC-1/sq-SF CTRP2 7.3322 12.218 3.9539 6.5813
HOP-92 GDSC2; CTRP2 7.363 13.3578 3.4199 8.6865
HCC95 CTRP2 7.3677 9.2127 5.3798 1.4335
NCI-H2291 GDSC2; CTRP2 7.4029 11.1589 4.5114 4.244
MOR/CPR CTRP2 7.4321 8.2083 5.7961 0.0458
NCI-H727 GDSC2; CTRP2 7.4651 12.4362 3.9411 7.5912
HCC2108 CTRP2 7.4708 10.3562 4.9294 2.7327
COLO 699 CTRP2 7.4914 9.5022 5.3205 1.5549
NCI-H2591 GDSC2 7.5089 9.8488 3.5574 0.4753
A-549 GDSC2; CTRP2 7.5178 12.4827 3.955 6.3026
NCI-H1838 GDSC2; CTRP2 7.595 11.7808 4.3427 4.653
ChaGo-K-1 GDSC2; CTRP2 7.6069 12.3717 4.0692 5.7201
HCC78 GDSC2; CTRP2 7.6314 11.0363 4.7143 3.7465
SHP-77 GDSC2; CTRP2 7.6389 12.8527 3.86 7.6709
NCI-H2126 CTRP2 7.6982 10.0054 5.2131 1.3161
HCC1833 CTRP2 7.715 12.5691 4.0473 5.6571
NCI-H1299 GDSC2; CTRP2 7.7383 12.9687 3.8719 6.7793
NCI-H460 GDSC2; CTRP2 7.7452 8.831 5.694 0.1037
NCI-H647 GDSC2; CTRP2 7.769 14.4597 3.173 9.0366
NCI-H1623 GDSC2; CTRP2 7.9059 11.7426 4.5566 3.4419
NCI-H1568 GDSC2; CTRP2 7.9103 14.7297 3.1413 8.9474
NCI-H1339 CTRP2 7.9179 12.0711 4.4124 3.9732
HCC15 GDSC2; CTRP2 7.9609 14.8001 3.1426 10.3729
NCI-H2085 GDSC2; CTRP2 7.9736 10.4775 5.1542 1.2822
NCI-H441 GDSC2; CTRP2 8.0104 9.7259 5.4723 0.4033
NCI-H2110 GDSC2; CTRP2 8.0174 13.2706 3.9136 5.7743
HCC827 GDSC2; CTRP2 8.0498 12.9127 4.103 5.3635
LXF 289 GDSC2; CTRP2 8.0641 10.5005 5.1896 1.1077
NCI-H358 GDSC2; CTRP2 8.0775 13.9532 3.629 7.9993
RERF-LC-MS GDSC2; CTRP2 8.0854 12.1619 4.4728 3.5499
HCC2279 CTRP2 8.0985 9.9131 5.4383 0.4394
NCI-H1435 GDSC2; CTRP2 8.1515 9.7306 5.5274 0.2485
IA-LM GDSC2; CTRP2 8.176 9.4732 5.6273 0.1049
NCI-H2023 GDSC2; CTRP2 8.1797 9.8004 5.513 0.2645
EPLC-272H GDSC2; CTRP2 8.2216 12.0996 4.5811 3.005
NCI-H2172 GDSC2; CTRP2 8.2936 9.5033 5.6582 0.0612
LUDLU-1 CTRP2 8.366 14.859 3.3894 7.3382
LOU-NH91 GDSC2; CTRP2 8.3707 10.3335 5.3927 0.4247
HOP-62 GDSC2; CTRP2 8.4023 13.8602 3.8832 5.3991
LCLC-103H GDSC2; CTRP2 8.4251 14.6526 3.5259 7.9073
KNS-62 GDSC2; CTRP2 8.4356 14.45 3.6282 6.3303
CAL-12T GDSC2; CTRP2 8.4811 10.2643 5.4619 0.2621
NCI-H1915 GDSC2; CTRP2 8.5947 14.2661 3.8147 5.4232
NCI-H1755 GDSC2; CTRP2 8.6148 10.4352 5.4517 0.2426
HCC2935 CTRP2 8.6487 10.3191 5.5052 0.1621
T3M-10 CTRP2 8.659 10.7563 5.3524 0.3982
NCI-H1355 GDSC2; CTRP2 8.6975 10.377 5.5028 0.1559
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2 8.8268 15.8673 3.213 8.6483
EKVX GDSC2; CTRP2 8.8339 11.0951 5.2974 0.4414
NCI-H2030 GDSC2; CTRP2 8.8365 10.4724 5.5196 0.1238
NCI-H2009 GDSC2; CTRP2 9.0198 16.5485 3.0167 9.1854
NCI-H1869 GDSC2; CTRP2 9.0671 10.6276 5.5471 0.0666
NCI-H2342 GDSC2; CTRP2 9.1385 10.8781 5.4877 0.1048
HCC1171 CTRP2 9.1904 10.9567 5.4792 0.1059
COR-L105 GDSC2; CTRP2 9.3112 16.7313 3.1161 7.1474
Lu-65 GDSC2; CTRP2 10.1113 22.6214 0.8513 13.8072
Calu-1 CTRP2 11.2884 21.5034 2.1245 8.2909
NCI-H1563 GDSC2; CTRP2 12.4421 23.3218 1.9749 7.5725
Hs 888.Lu CTRP2 7.1363 10.6814 4.5607 4.4169
⏷ Show the Full List of 219 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 3.301 6.3664 2.3607 14.2972
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
P-STS CTRP2 2.9641 6.9936 2.3829 22.592
SYO-1 CTRP2 5.8287 10.015 3.8766 9.5315
H-STS CTRP2 5.9328 6.5756 5.6809 1.7578
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 4.7212 13.2289 1.2975 21.9215
A2780 GDSC2 1.5727 4.5431 1.2584 26.5609
JHOS-4 GDSC2 3.6058 8.9225 0.7545 15.0999
TOV-112D GDSC2; CTRP2 4.2408 6.4613 3.9483 13.0603
OVK18 GDSC2; CTRP2 4.4592 8.3721 3.3916 14.6361
OVKATE GDSC2 4.6875 6.7366 2.5735 1.9467
COV434 CTRP2 4.9442 10.901 2.6477 16.4467
TYK-nu GDSC2; CTRP2 5.0138 7.4396 4.3733 9.3047
SNU-119 CTRP2 5.1727 8.7029 3.9335 10.7108
Caov-4 GDSC2 5.2001 7.7033 2.4276 2.0107
EFO-27 GDSC2; CTRP2 5.2607 8.5726 4.0797 9.9061
ONCO-DG-1 CTRP2 5.3896 14.2375 1.3901 25.7525
ES-2 GDSC2 5.6312 8.5529 3.1725 3.8485
OC 314 GDSC2; CTRP2 5.6627 6.7411 5.3429 3.7789
OAW42 GDSC2; CTRP2 5.7025 11.3499 3.1016 12.9889
OVCAR-5 GDSC2; CTRP2 5.7762 10.6759 3.5015 11.1978
JHOS-2 GDSC2; CTRP2 5.8493 14.0377 1.8841 17.4057
IGROV-1 GDSC2; CTRP2 5.8647 9.815 4.0074 8.9124
OVCAR-3 GDSC2 5.8744 8.1127 3.5105 1.831
SNU-8 CTRP2 6.0094 8.0104 5.0321 5.8934
DOV13 GDSC2; CTRP2 6.1823 8.8418 4.7589 6.0844
MCAS CTRP2 6.3516 8.0024 5.3082 2.5498
HEY A8 CTRP2 6.4329 8.4975 5.1247 3.1778
OV7 CTRP2 6.6389 11.6444 3.7231 8.6523
JHOC-5 CTRP2 6.7103 8.1702 5.4719 1.384
TOV-21G GDSC2; CTRP2 6.912 12.7864 3.3664 9.6423
OVSAHO CTRP2 6.9277 9.3837 5.0411 3.7979
EFO-21 GDSC2; CTRP2 6.9292 10.0624 4.7165 4.0873
OVCAR-8 GDSC2; CTRP2 7.1013 9.0645 5.2977 1.5909
COV644 CTRP2 7.1248 12.5391 3.6475 8.1479
ES2 CTRP2 7.1345 9.1914 5.2598 2.3093
OV56 GDSC2; CTRP2 7.1681 8.3235 5.6498 0.3908
RMG-I GDSC2; CTRP2 7.359 12.6575 3.7591 7.3279
SK-OV-3 GDSC2; CTRP2 7.3683 8.8763 5.5205 0.6203
OVCAR-4 GDSC2; CTRP2 7.3689 9.96 5.0493 2.2123
Caov-3 GDSC2; CTRP2 7.3802 9.3688 5.3191 1.2412
COV362 CTRP2 7.6061 13.7364 3.4094 8.3517
SNU-840 CTRP2 7.6406 10.8391 4.8105 2.7949
OVISE GDSC2; CTRP2 7.9422 9.5823 5.4982 0.4455
JHOM-1 CTRP2 7.9778 9.2739 5.6245 0.1456
OVTOKO GDSC2; CTRP2 7.9867 12.486 4.2625 5.271
FU-OV-1 GDSC2; CTRP2 8.0604 9.8935 5.4297 0.4751
Kuramochi GDSC2; CTRP2 8.145 10.2152 5.342 0.7588
OV-90 GDSC2; CTRP2 8.3641 9.9206 5.5401 0.1752
OAW28 GDSC2; CTRP2 8.6976 10.9692 5.2888 0.5098
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 7.1171 9.7709 4.9813 2.7728
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 7.8107 9.6875 5.4 0.6776
Aska-SS CTRP2 8.6218 15.3236 3.3368 7.198
KYM-1 GDSC2; CTRP2 1.7991 5.419 1.566 29.0707
TE 617.T CTRP2 2.0706 5.7588 1.7822 27.4605
TE 441.T GDSC2; CTRP2 2.4909 4.9644 2.399 23.986
G-402 GDSC2; CTRP2 2.5559 6.4415 2.1219 24.7577
Hs 633.T GDSC2 3.3964 5.8344 2.1272 7.3491
STS-0421 GDSC2 3.6474 7.0024 1.7454 9.0569
G-401 GDSC2; CTRP2 3.671 8.6287 2.4756 20.2596
A-204 GDSC2; CTRP2 3.789 7.8132 2.9469 18.1387
TTC-709 CTRP2 4.281 11.1689 1.8966 20.8627
MFH-ino GDSC2 4.8158 7.5693 2.2762 3.3329
GCT GDSC2; CTRP2 4.9755 7.4327 4.3376 9.5449
EW-8 GDSC2 5.0788 8.2584 2.9433 6.1387
MES-SA GDSC2; CTRP2 5.1964 9.5156 3.5598 12.1946
HT-1080 GDSC2; CTRP2 5.3736 6.2269 5.2554 4.8924
SW684 GDSC2 5.496 6.6454 3.9323 0.4807
Hs 729.T CTRP2 6.0404 9.2305 4.448 6.7177
VA-ES-BJ GDSC2 6.0906 11.4003 2.1261 8.5419
BT-12 CTRP2 6.132 7.8949 5.1911 3.4213
SW872 GDSC2 6.3593 8.1989 3.7056 0.6422
Rh41 GDSC2; CTRP2 6.4661 9.004 4.8996 4.7992
RKN GDSC2; CTRP2 6.5023 7.4818 5.662 0.9087
Tm87-16 CTRP2 6.864 15.1834 2.1386 14.5194
Rh30 GDSC2 6.8778 9.0926 3.5841 0.7008
SW982 GDSC2; CTRP2 6.9576 11.8847 3.846 7.6083
Rh18 CTRP2 7.4205 8.8172 5.5683 0.4601
SK-LMS-1 GDSC2; CTRP2 7.4846 11.3686 4.4656 4.3156
BT-16 CTRP2 7.8219 9.2869 5.5595 0.2986
SK-UT-1 GDSC2; CTRP2 11.0968 20.1359 2.6307 6.8311
RD GDSC2; CTRP2 13.1228 25.9741 1.1776 9.285
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2; CTRP2 5.6332 9.0714 4.176 8.6841
NCI-H28 GDSC2; CTRP2 5.9794 9.6335 4.1954 9.3379
NCI-H2052 GDSC2; CTRP2 6.2239 8.5401 4.9428 4.2954
MPP 89 GDSC2; CTRP2 6.3904 9.9159 4.3889 6.3182
NCI-H2452 GDSC2; CTRP2 6.7238 10.919 3.361 5.6553
JL-1 CTRP2 7.0098 8.801 5.3633 1.4499
ACC-MESO-1 CTRP2 8.192 9.3944 5.6597 0.0972
IST-Mes1 GDSC2; CTRP2 10.2302 19.5801 2.3654 8.6965
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2; CTRP2 3.4365 7.1175 2.8471 19.5024
NCI-H660 GDSC2 4.5857 6.3293 2.695 1.4744
DU145 GDSC2; CTRP2 6.0186 7.0559 5.517 2.267
22Rv1 GDSC2; CTRP2 6.2425 10.7677 3.8457 10.4584
PC-3 GDSC2 6.4918 8.6719 3.58 0.9629
VCaP GDSC2; CTRP2 6.9826 11.9219 3.8462 7.5669
PaCa-3 CTRP2 7.564 8.9401 5.5832 0.3532
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2; CTRP2 5.3189 8.7385 4.0535 9.8815
YD-15 CTRP2 6.8236 9.1425 5.0867 2.7465
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 3.5449 7.521 2.0362 15.3009
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-16 GDSC2; CTRP2 2.8737 6.1819 2.5456 22.272
HSC-39 GDSC2 3.1345 5.6037 2.0213 8.7944
TGBC11TKB GDSC2 3.8612 6.3054 2.2523 5.3557
GSS CTRP2 4.2745 7.531 3.5724 19.6111
TMK-1 GDSC2 4.4602 7.3845 2.1429 4.7287
RF-48 GDSC2 4.7134 7.2504 3.1697 5.6641
HGC-27 GDSC2; CTRP2 4.7529 8.3952 3.6736 12.7717
SCH GDSC2 4.7618 7.8636 2.1094 4.3578
SNU-620 CTRP2 4.8907 7.7188 4.1227 14.4732
ECC10 GDSC2; CTRP2 4.9299 7.1703 4.4068 9.3885
OCUM-1 GDSC2 4.9542 10.4127 1.7861 12.7923
NUGC-4 GDSC2; CTRP2 4.9877 8.7256 3.7462 11.9108
SNU-216 CTRP2 5.2587 11.2421 2.7649 15.2829
SK-GT-2 GDSC2 5.3961 9.0991 2.7585 6.5108
SNU-1 GDSC2; CTRP2 5.4182 8.7524 4.1387 9.3063
GCIY GDSC2 5.4255 10.1502 2.2685 9.1278
SNU-5 GDSC2; CTRP2 5.4653 8.4026 4.3537 8.3092
MKN1 GDSC2 5.5605 10.5459 2.172 9.3615
NCC-StC-K140 CTRP2 5.629 8.1902 4.6083 6.8893
IM95 GDSC2; CTRP2 5.8401 16.6693 0.5607 21.8582
NUGC-3 GDSC2; CTRP2 6.0276 8.6537 4.7257 5.5753
KATO III GDSC2; CTRP2 6.1368 8.0278 5.1286 3.6748
RERF-GC-1B GDSC2 6.1847 11.6448 2.0723 8.6413
SNU-601 CTRP2 6.3035 9.9457 4.3052 6.8243
SNU-719 CTRP2 6.4645 12.451 3.1841 11.1734
NCI-N87 GDSC2; CTRP2 6.6305 10.6637 4.2032 6.6767
23132/87 GDSC2; CTRP2 6.8053 9.9896 4.6644 5.307
AGS GDSC2; CTRP2 6.8074 8.8787 5.2015 2.3124
Fu97 GDSC2; CTRP2 6.8178 11.2737 4.043 7.0271
GSU CTRP2 6.9208 7.5593 5.8359 0.1262
MKN45 GDSC2; CTRP2 7.0335 8.3235 5.5854 0.7873
HuG1-N CTRP2 7.153 10.4558 4.6801 3.9145
MKN28 GDSC2 7.2204 13.3251 1.9454 7.4754
MKN7 GDSC2; CTRP2 7.2564 9.7051 5.0983 2.1566
SNU-668 CTRP2 7.4691 8.9336 5.5442 0.4951
SH-10-TC CTRP2 7.6431 8.9512 5.6118 0.2616
ECC12 GDSC2; CTRP2 7.7578 9.1659 5.5785 0.337
KE-39 CTRP2 8.2948 14.11 3.6974 6.2472
LMSU CTRP2 8.4386 13.2926 4.1678 4.2835
MKN74 CTRP2 8.4686 10.4844 5.3764 0.4203
Hs 746.T GDSC2; CTRP2 9.7172 16.7901 3.336 5.8816
SNG-M GDSC2; CTRP2 6.4577 9.8617 4.4683 5.8683
SNU-685 CTRP2 7.6213 9.1551 5.525 0.4621
SNU-1077 CTRP2 8.5699 10.1513 5.5348 0.1928
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMH-2 GDSC2 3.9314 8.2715 1.3349 10.8229
IHH-4 GDSC2 4.3141 6.137 3.4078 5.2805
K5 GDSC2 4.3497 6.774 3.1189 6.8488
TT2609-C02 GDSC2; CTRP2 4.5358 6.5242 4.2459 11.0932
ML-1 [Human leukemia] GDSC2; CTRP2 5.528 7.637 4.1257 3.8811
SW579 CTRP2 5.8447 8.0937 4.8488 5.4246
CAL-62 GDSC2; CTRP2 5.9228 7.2563 5.3344 3.8186
WRO GDSC2 6.1841 13.6067 1.1251 13.3355
FTC-238 CTRP2 6.2231 7.2305 5.5929 1.5794
HTC-C3 GDSC2 6.3262 8.3872 3.618 0.9544
8505C GDSC2; CTRP2 6.3414 9.0794 4.7667 4.8241
ASH-3 GDSC2 6.3575 7.9285 3.8059 0.3678
FTC-133 GDSC2; CTRP2 6.3726 9.4834 4.5902 5.5077
BHT-101 GDSC2; CTRP2 6.8255 8.859 5.2227 2.2052
8305C GDSC2; CTRP2 6.9716 9.3962 5.0639 3.1207
CGTH-W-1 GDSC2; CTRP2 7.2749 9.482 5.2105 2.0392
TT GDSC2; CTRP2 7.6226 9.2705 5.4802 0.5749
B-CPAP GDSC2; CTRP2 8.1409 12.1765 4.4992 4.0075
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-15A GDSC2 1.3425 3.5229 1.1036 21.1313
JHU-011 GDSC2 3.3006 5.2165 2.3568 6.1731
BB30-HNC GDSC2 3.3102 4.8219 2.5622 4.8446
KOSC-2 GDSC2 3.5865 6.4628 1.9661 7.84
PCI-06A GDSC2 3.9245 6.2168 2.3407 4.6637
OSC-19 GDSC2 4.043 8.1458 1.4814 9.6562
JHU-029 GDSC2 4.6499 9.8589 1.0832 10.5458
FaDu GDSC2; CTRP2 4.7008 10.17 2.7773 16.4987
KON GDSC2 4.77 10.7084 0.7549 12.1009
PCI-30 GDSC2 4.7911 7.9863 2.0707 4.5255
UPCI-SCC-090 GDSC2 4.8656 8.4677 2.6829 8.0754
SAS GDSC2 4.9771 8.6906 2.6567 7.968
DOK GDSC2 5.0497 9.2043 2.4576 8.9158
HO-1-u-1 GDSC2 5.1458 8.7093 1.9537 4.566
HO-1-N-1 GDSC2 5.2148 7.8006 3.2586 4.1221
PCI-04B GDSC2 5.5301 7.9748 3.3772 2.9515
SKN-3 GDSC2 5.5386 11.993 1.4471 13.1714
BICR 10 GDSC2 5.6853 10.4473 2.3076 8.3785
NCI-H3118 GDSC2 5.7677 8.2872 3.3752 2.6091
HSC-4 GDSC2; CTRP2 5.8567 8.236 4.7885 5.6528
HSC-2 GDSC2; CTRP2 5.9468 9.536 4.2166 7.8723
PE/CA-PJ49 CTRP2 5.9658 6.8885 5.5552 2.2131
JHU-022 GDSC2 5.9893 10.181 2.6381 6.0443
BB49-HNC GDSC2 6.0286 15.2886 0.1878 17.7861
Ca9-22 GDSC2 6.0678 8.5877 3.4082 2.0642
SCC-4 GDSC2; CTRP2 6.3702 7.7211 5.4596 1.896
YD-8 CTRP2 6.3996 11.2181 3.7473 8.9783
YD-10B CTRP2 6.4768 8.1836 5.3102 2.3447
BICR 78 GDSC2 6.5295 8.3519 3.7186 0.5106
SCC-15 GDSC2 6.533 9.5791 3.227 2.3348
PE/CA-PJ34 (clone C12) CTRP2 6.595 9.9572 4.5258 5.3957
SCC-25 GDSC2; CTRP2 6.6307 9.9987 4.532 5.3107
OSC-20 GDSC2 6.6357 8.8964 3.5558 0.9414
LB771-HNC GDSC2 6.6775 8.2461 3.814 0.2359
BICR 6 CTRP2 6.7514 8.1049 5.5267 1.1312
PE/CA-PJ15 GDSC2; CTRP2 6.9595 13.0438 3.275 9.9309
HSC-3 GDSC2; CTRP2 6.9772 9.4843 5.0259 3.2889
SNU-899 CTRP2 6.9904 8.5889 5.4472 1.1678
PE/CA-PJ41 (clone D2) CTRP2 7.0761 13.6086 3.0839 10.4998
SNU-1214 CTRP2 7.1293 10.1081 4.83 3.3511
CAL-33 GDSC2; CTRP2 7.1508 11.5405 4.1549 6.0399
SAT [Human HNSCC] GDSC2 7.2462 15.1432 1.1113 11.3455
BICR 18 CTRP2 7.3202 12.1258 3.9902 6.4525
CAL-27 GDSC2; CTRP2 7.3216 8.8413 5.5125 0.675
SNU-1076 CTRP2 7.5436 12.1255 4.1443 7.4712
Detroit 562 GDSC2; CTRP2 7.5726 9.3135 5.4396 0.8473
BICR 16 CTRP2 7.6442 11.8256 4.3536 4.5452
BHY GDSC2; CTRP2 7.7336 11.361 4.6273 3.9933
BICR 56 CTRP2 7.8005 9.1152 5.614 0.2064
SCC-9 GDSC2; CTRP2 7.9683 10.9675 4.941 1.9874
SNU-1066 CTRP2 8.0397 9.5521 5.5486 0.3352
BICR 22 GDSC2; CTRP2 8.0967 13.4032 3.9025 5.7132
SNU-1041 CTRP2 8.1955 12.3862 4.4363 4.8407
BICR 31 GDSC2; CTRP2 8.861 10.5397 5.5053 0.126
SNU-46 CTRP2 8.8873 10.5571 5.5087 0.1187
⏷ Show the Full List of 55 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BFTC-905 GDSC2 4.5824 8.151 2.6199 9.1123
SW780 GDSC2 5.1377 8.4833 2.8757 6.392
253J CTRP2 5.1798 9.8511 3.3799 17.5445
CAL-29 GDSC2; CTRP2 5.6686 6.4543 5.4791 3.8066
639V GDSC2; CTRP2 6.096 7.5867 5.3158 3.5071
TCCSUP GDSC2; CTRP2 6.1597 8.5601 4.8813 4.6706
UM-UC-3 GDSC2; CTRP2 6.472 8.9075 4.9516 3.8311
JMSU-1 CTRP2 6.5176 8.6021 5.1353 4.0887
253J-BV CTRP2 6.5391 10.0681 4.4284 8.026
U-BLC1 CTRP2 6.7927 12.8451 3.2457 10.3365
647V GDSC2; CTRP2 7.1272 8.7917 5.4336 1.0836
VM-CUB-1 CTRP2 7.1723 9.0245 5.3562 1.784
SCaBER CTRP2 7.2381 10.6596 4.6398 3.9582
RT-112 GDSC2; CTRP2 7.2802 8.7261 5.5398 0.6237
HT-1376 GDSC2; CTRP2 7.3394 9.043 5.4372 0.8907
5637 GDSC2; CTRP2 7.3946 9.5261 5.2583 1.435
KU-19-19 GDSC2; CTRP2 7.7154 13.1786 3.7556 8.0239
J82 GDSC2; CTRP2 7.8419 12.6853 4.0759 5.3727
KMBC-2 CTRP2 8.0409 10.0096 5.3763 0.6106
BC-3C CTRP2 8.079 14.2594 3.4838 7.3678
HT-1197 GDSC2; CTRP2 8.1922 14.5707 3.4111 7.4927
RT-4 GDSC2; CTRP2 8.2618 15.4507 3.0363 8.8383
SW1710 GDSC2; CTRP2 8.6037 10.2365 5.5175 0.1556
T24 GDSC2; CTRP2 9.6909 16.6249 3.3955 5.699
UM-UC-1 CTRP2 10.6766 20.5904 2.1736 8.819
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NEC8 GDSC2 0.9522 2.2763 0.9477 30.7521
NT2-D1 GDSC2 1.2358 5.3197 0.3039 25.9235
JEG-3 GDSC2 1.3915 7.3409 -0.4586 28.8479
JAR GDSC2 1.4955 4.5358 0.9032 21.5773
PA-1 GDSC2 1.7959 7.0084 0.5517 28.8377
TC-YIK GDSC2 1.9919 5.4615 1.3972 24.1546
SW954 GDSC2 3.4122 5.1271 2.4935 4.9887
KGN GDSC2 3.6004 9.6135 0.4051 17.0315
ME-180 GDSC2 3.8553 7.1027 2.5258 11.6267
OVCA433 GDSC2 3.8558 6.6784 2.0652 6.5294
UWB1.289 GDSC2 4.4054 8.3189 1.6586 7.7313
DSH1 GDSC2 4.4145 7.6522 2.7333 8.8921
ACC-OV7 GDSC2 4.5526 10.8391 0.5332 13.817
HEY GDSC2 4.56 8.306 2.5247 9.7076
JHOS-3 GDSC2 4.8315 6.884 2.586 1.6986
OMC-1 [Human cervical carcinoma] GDSC2 4.8701 8.5524 1.8568 5.6055
SW962 GDSC2 4.8901 6.7191 2.684 1.182
SiSo GDSC2 4.9137 8.1748 2.8637 6.9451
PWR-1E GDSC2 5.1825 7.7091 3.2807 4.0624
C-33 A GDSC2 5.261 8.6077 2.9022 5.9909
BPH-1 GDSC2 5.2707 11.0728 1.7009 12.49
SiHa GDSC2 5.3423 7.8083 3.338 3.4647
CAL-39 GDSC2 5.3939 8.4746 3.0567 4.8851
HEC-1 GDSC2 5.5847 9.881 2.5114 7.4819
NCC-IT GDSC2 5.6253 7.34 2.7609 0.399
OVMIU GDSC2 5.8536 11.4581 1.9357 10.0004
PEO1 GDSC2 5.8996 8.5305 3.3415 2.5904
OV17R GDSC2 5.9875 8.1087 2.6227 0.594
C-4-I GDSC2 6.156 8.8594 3.3378 2.279
SW756 GDSC2 6.3041 9.4789 3.1479 2.9772
SKN GDSC2 6.4128 8.6173 3.5659 1.073
OVCA420 GDSC2 6.4467 8.1822 3.7481 0.4731
DoTc2 4510 GDSC2 6.502 8.2734 3.7366 0.4764
HT-3 GDSC2 6.5533 9.0834 3.4437 1.4127
MS751 GDSC2 6.5997 8.8066 3.5751 0.9024
SKG-IIIa GDSC2 6.6981 8.1891 3.8414 0.1838
LB831-BLC GDSC2 6.7339 9.0227 3.5497 0.8943
HeLa GDSC2; CTRP2 7.0995 8.0674 5.7194 0.256
Ca Ski GDSC2 7.5298 9.658 3.6331 0.3162
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxaliplatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Ivosidenib. Acute myeloid leukaemia [2A60] [16]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Midostaurin. Acute myeloid leukaemia [2A60] [17]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Oliceridine. Acute pain [MG31] [17]
Framycetin DMF8DNE Moderate Decreased renal excretion of Oxaliplatin caused by Framycetin mediated nephrotoxicity. Alcoholic liver disease [DB94] [19]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Galantamine. Alzheimer disease [8A20] [17]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Rivastigmine. Alzheimer disease [8A20] [17]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Donepezil. Alzheimer disease [8A20] [17]
Inotersen DMJ93CT Moderate Decreased renal excretion of Oxaliplatin caused by Inotersen mediated nephrotoxicity. Amyloidosis [5D00] [19]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ivabradine. Angina pectoris [BA40] [20]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Bepridil. Angina pectoris [BA40] [17]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Dronedarone. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [17]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Cilostazol. Arterial occlusive disease [BD40] [17]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Voriconazole. Aspergillosis [1F20] [17]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Posaconazole. Aspergillosis [1F20] [17]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levalbuterol. Asthma [CA23] [22]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Terbutaline. Asthma [CA23] [23]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pirbuterol. Asthma [CA23] [23]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Salbutamol. Asthma [CA23] [22]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Roflumilast. Asthma [CA23] [20]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Formoterol. Asthma [CA23] [23]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [20]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Desipramine. Attention deficit hyperactivity disorder [6A05] [17]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ofloxacin. Bacterial infection [1A00-1C4Z] [24]
Kanamycin DM2DMPO Moderate Decreased renal excretion of Oxaliplatin caused by Kanamycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [19]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [17]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clarithromycin. Bacterial infection [1A00-1C4Z] [17]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Oxaliplatin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [24]
Streptomycin DME1LQN Moderate Decreased renal excretion of Oxaliplatin caused by Streptomycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [19]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [24]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Norfloxacin. Bacterial infection [1A00-1C4Z] [24]
Gentamicin DMKINJO Moderate Decreased renal excretion of Oxaliplatin caused by Gentamicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [19]
Netilmicin DMRD1QK Moderate Decreased renal excretion of Oxaliplatin caused by Netilmicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [19]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levofloxacin. Bacterial infection [1A00-1C4Z] [24]
Tobramycin DMUI0CH Moderate Decreased renal excretion of Oxaliplatin caused by Tobramycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [19]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [17]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Telithromycin. Bacterial infection [1A00-1C4Z] [17]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Retigabine. Behcet disease [4A62] [17]
Etidronic acid DM1XHYJ Moderate Decreased renal excretion of Oxaliplatin caused by Etidronic acid mediated nephrotoxicity. Bone paget disease [FB85] [19]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [25]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Eribulin. Breast cancer [2C60-2C6Y] [17]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lapatinib. Breast cancer [2C60-2C6Y] [17]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tamoxifen. Breast cancer [2C60-2C6Y] [17]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Toremifene. Breast cancer [2C60-2C6Y] [17]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Bosutinib. Breast cancer [2C60-2C6Y] [20]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [26]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [23]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [23]
Phenylbutazone DMAYL0T Moderate Decreased renal excretion of Oxaliplatin caused by Phenylbutazone mediated nephrotoxicity. Chronic pain [MG30] [19]
Ketoprofen DMRKXPT Moderate Decreased renal excretion of Oxaliplatin caused by Ketoprofen mediated nephrotoxicity. Chronic pain [MG30] [19]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Isoproterenol. Conduction disorder [BC63] [22]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Halothane. Corneal disease [9A76-9A78] [17]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Propofol. Corneal disease [9A76-9A78] [27]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sevoflurane. Corneal disease [9A76-9A78] [17]
Methoxyflurane DML0RAE Moderate Decreased renal excretion of Oxaliplatin caused by Methoxyflurane mediated nephrotoxicity. Corneal disease [9A76-9A78] [19]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Probucol. Coronary atherosclerosis [BA80] [17]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clofazimine. Crohn disease [DD70] [28]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Mifepristone. Cushing syndrome [5A70] [17]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Pasireotide. Cushing syndrome [5A70] [17]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Osilodrostat. Cushing syndrome [5A70] [20]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sertraline. Depression [6A70-6A7Z] [17]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trimipramine. Depression [6A70-6A7Z] [17]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Nortriptyline. Depression [6A70-6A7Z] [17]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Escitalopram. Depression [6A70-6A7Z] [17]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clomipramine. Depression [6A70-6A7Z] [17]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trazodone. Depression [6A70-6A7Z] [29]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Amoxapine. Depression [6A70-6A7Z] [17]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Doxepin. Depression [6A70-6A7Z] [17]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Maprotiline. Depression [6A70-6A7Z] [17]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [17]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Deutetrabenazine. Dystonic disorder [8A02] [30]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Oxaliplatin and Ingrezza. Dystonic disorder [8A02] [31]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Cannabidiol. Epileptic encephalopathy [8A62] [20]
Mefenamic acid DMK7HFI Moderate Decreased renal excretion of Oxaliplatin caused by Mefenamic acid mediated nephrotoxicity. Female pelvic pain [GA34] [19]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Solifenacin. Functional bladder disorder [GC50] [17]
Pentamidine DMHZJCG Moderate Decreased renal excretion of Oxaliplatin caused by Pentamidine mediated nephrotoxicity. Fungal infection [1F29-1F2F] [19]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ketoconazole. Fungal infection [1F29-1F2F] [17]
Amphotericin B DMTAJQE Moderate Decreased renal excretion of Oxaliplatin caused by Amphotericin B mediated nephrotoxicity. Fungal infection [1F29-1F2F] [19]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [17]
177Lu-DOTATATE DMT8GVU Moderate Decreased renal excretion of Oxaliplatin caused by 177Lu-DOTATATE mediated nephrotoxicity. Hepatitis virus infection [1E50-1E51] [19]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [33]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [34]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Oxaliplatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [36]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [17]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [37]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and BMS-201038. Hyper-lipoproteinaemia [5C80] [39]
Givosiran DM5PFIJ Moderate Decreased renal excretion of Oxaliplatin caused by Givosiran mediated nephrotoxicity. Inborn porphyrin/heme metabolism error [5C58] [19]
Balsalazide DM7I1T9 Moderate Decreased renal excretion of Oxaliplatin caused by Balsalazide mediated nephrotoxicity. Indeterminate colitis [DD72] [19]
Meclofenamic acid DM05FXR Moderate Decreased renal excretion of Oxaliplatin caused by Meclofenamic acid mediated nephrotoxicity. Inflammatory spondyloarthritis [FA92] [19]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Phenolphthalein. Irritable bowel syndrome [DD91] [17]
Methotrexate DM2TEOL Moderate Decreased renal excretion of Oxaliplatin caused by Methotrexate mediated nephrotoxicity. Leukaemia [2A60-2B33] [19]
Ibandronate DM0QZBN Moderate Decreased renal excretion of Oxaliplatin caused by Ibandronate mediated nephrotoxicity. Low bone mass disorder [FB83] [19]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Denosumab. Low bone mass disorder [FB83] [40]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Crizotinib. Lung cancer [2C25] [41]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Ceritinib. Lung cancer [2C25] [17]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Selpercatinib. Lung cancer [2C25] [20]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Lumefantrine. Malaria [1F40-1F45] [15]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Halofantrine. Malaria [1F40-1F45] [43]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Chloroquine. Malaria [1F40-1F45] [44]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Hydroxychloroquine. Malaria [1F40-1F45] [44]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Primaquine. Malaria [1F40-1F45] [17]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [20]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [45]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Idelalisib. Mature B-cell leukaemia [2A82] [46]
Moxetumomab pasudotox DMN63DZ Moderate Decreased renal excretion of Oxaliplatin caused by Moxetumomab pasudotox mediated nephrotoxicity. Mature B-cell leukaemia [2A82] [19]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Clofarabine. Mature B-cell lymphoma [2A85] [47]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Vemurafenib. Melanoma [2C30] [17]
Exjade DMHPRWG Moderate Decreased renal excretion of Oxaliplatin caused by Exjade mediated nephrotoxicity. Mineral absorption/transport disorder [5C64] [19]
Gallium nitrate DMF9O6B Moderate Decreased renal excretion of Oxaliplatin caused by Gallium nitrate mediated nephrotoxicity. Mineral excesses [5B91] [19]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Panobinostat. Multiple myeloma [2A83] [48]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Oxaliplatin and Thalidomide. Multiple myeloma [2A83] [49]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Tecfidera. Multiple sclerosis [8A40] [50]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Oxaliplatin and Siponimod. Multiple sclerosis [8A40] [15]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Fingolimod. Multiple sclerosis [8A40] [51]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Ocrelizumab. Multiple sclerosis [8A40] [52]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ozanimod. Multiple sclerosis [8A40] [20]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Romidepsin. Mycosis fungoides [2B01] [17]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Nilotinib. Myeloproliferative neoplasm [2A20] [17]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Dasatinib. Myeloproliferative neoplasm [2A20] [53]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [54]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Promethazine. Nausea/vomiting [MD90] [17]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Granisetron. Nausea/vomiting [MD90] [17]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Dolasetron. Nausea/vomiting [MD90] [17]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ondansetron. Nausea/vomiting [MD90] [17]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Entrectinib. Non-small cell lung cancer [2C25] [15]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Levomethadyl Acetate. Opioid use disorder [6C43] [20]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Oxaliplatin and Lofexidine. Opioid use disorder [6C43] [17]
Rofecoxib DM3P5DA Moderate Decreased renal excretion of Oxaliplatin caused by Rofecoxib mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [19]
Valdecoxib DMAY7H4 Moderate Decreased renal excretion of Oxaliplatin caused by Valdecoxib mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [19]
Diclofenac DMPIHLS Moderate Decreased renal excretion of Oxaliplatin caused by Diclofenac mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [19]
Naproxen DMZ5RGV Moderate Decreased renal excretion of Oxaliplatin caused by Naproxen mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [19]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Rucaparib. Ovarian cancer [2C73] [17]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Dextropropoxyphene. Pain [MG30-MG3Z] [55]
Etodolac DM6WJO9 Moderate Decreased renal excretion of Oxaliplatin caused by Etodolac mediated nephrotoxicity. Pain [MG30-MG3Z] [19]
Diflunisal DM7EN8I Moderate Decreased renal excretion of Oxaliplatin caused by Diflunisal mediated nephrotoxicity. Pain [MG30-MG3Z] [19]
Ibuprofen DM8VCBE Moderate Decreased renal excretion of Oxaliplatin caused by Ibuprofen mediated nephrotoxicity. Pain [MG30-MG3Z] [19]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Buprenorphine. Pain [MG30-MG3Z] [17]
Piroxicam DMTK234 Moderate Decreased renal excretion of Oxaliplatin caused by Piroxicam mediated nephrotoxicity. Pain [MG30-MG3Z] [19]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Triclabendazole. Parasitic worm infestation [1F90] [17]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pimavanserin. Parkinsonism [8A00] [56]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Apomorphine. Parkinsonism [8A00] [17]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Famotidine. Peptic ulcer [DA61] [15]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Macimorelin. Pituitary gland disorder [5A60-5A61] [57]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Lefamulin. Pneumonia [CA40] [58]
Bromfenac DMKB79O Moderate Decreased renal excretion of Oxaliplatin caused by Bromfenac mediated nephrotoxicity. Postoperative inflammation [1A00-CA43] [19]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ritodrine. Preterm labour/delivery [JB00] [23]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Degarelix. Prostate cancer [2C82] [20]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and ABIRATERONE. Prostate cancer [2C82] [20]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Nilutamide. Prostate cancer [2C82] [20]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Enzalutamide. Prostate cancer [2C82] [20]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Relugolix. Prostate cancer [2C82] [20]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Bicalutamide. Prostate cancer [2C82] [20]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levomepromazine. Psychotic disorder [6A20-6A25] [17]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Fluphenazine. Psychotic disorder [6A20-6A25] [17]
Temsirolimus DMS104F Moderate Decreased renal excretion of Oxaliplatin caused by Temsirolimus mediated nephrotoxicity. Renal cell carcinoma [2C90] [19]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [59]
Colistimethate DMZ9BMU Moderate Decreased renal excretion of Oxaliplatin caused by Colistimethate mediated nephrotoxicity. Respiratory infection [CA07-CA4Z] [19]
Salsalate DM13P4C Moderate Decreased renal excretion of Oxaliplatin caused by Salsalate mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Meloxicam DM2AR7L Moderate Decreased renal excretion of Oxaliplatin caused by Meloxicam mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Sulindac DM2QHZU Moderate Decreased renal excretion of Oxaliplatin caused by Sulindac mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Canakinumab. Rheumatoid arthritis [FA20] [60]
Oxaprozin DM9UB0P Moderate Decreased renal excretion of Oxaliplatin caused by Oxaprozin mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Rilonacept. Rheumatoid arthritis [FA20] [60]
Flurbiprofen DMGN4BY Moderate Decreased renal excretion of Oxaliplatin caused by Flurbiprofen mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Oxaliplatin and Golimumab. Rheumatoid arthritis [FA20] [61]
Sulfasalazine DMICA9H Moderate Decreased renal excretion of Oxaliplatin caused by Sulfasalazine mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Fenoprofen DML5VQ0 Moderate Decreased renal excretion of Oxaliplatin caused by Fenoprofen mediated nephrotoxicity. Rheumatoid arthritis [FA20] [19]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Oxaliplatin and Leflunomide. Rheumatoid arthritis [FA20] [38]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Quetiapine. Schizophrenia [6A20] [17]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Mesoridazine. Schizophrenia [6A20] [17]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Thioridazine. Schizophrenia [6A20] [17]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Aripiprazole. Schizophrenia [6A20] [15]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Iloperidone. Schizophrenia [6A20] [17]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Paliperidone. Schizophrenia [6A20] [17]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Perphenazine. Schizophrenia [6A20] [17]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trifluoperazine. Schizophrenia [6A20] [17]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Risperidone. Schizophrenia [6A20] [17]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Amisulpride. Schizophrenia [6A20] [62]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Asenapine. Schizophrenia [6A20] [17]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Pimozide. Schizophrenia [6A20] [20]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Oxaliplatin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [63]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Vardenafil. Sexual dysfunction [HA00-HA01] [17]
Bacitracin DM5OHYE Moderate Decreased renal excretion of Oxaliplatin caused by Bacitracin mediated nephrotoxicity. Skin and skin-structure infection [1F28-1G0Z] [19]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [20]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Oxaliplatin and LEE011. Solid tumour/cancer [2A00-2F9Z] [17]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [17]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pitolisant. Somnolence [MG42] [17]
Telavancin DM58VQX Moderate Decreased renal excretion of Oxaliplatin caused by Telavancin mediated nephrotoxicity. Staphylococcal/streptococcal disease [1B5Y] [19]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Naltrexone. Substance abuse [6C40] [64]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Adenosine. Supraventricular tachyarrhythmia [BC81] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lenvatinib. Thyroid cancer [2D10] [17]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Cabozantinib. Thyroid cancer [2D10] [20]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Papaverine. Tonus and reflex abnormality [MB47] [65]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tizanidine. Tonus and reflex abnormality [MB47] [17]
Sirolimus DMGW1ID Moderate Decreased renal excretion of Oxaliplatin caused by Sirolimus mediated nephrotoxicity. Transplant rejection [NE84] [19]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Azathioprine. Transplant rejection [NE84] [15]
Tacrolimus DMZ7XNQ Moderate Decreased renal excretion of Oxaliplatin caused by Tacrolimus mediated nephrotoxicity. Transplant rejection [NE84] [19]
Olsalazine DMZW9HA Moderate Decreased renal excretion of Oxaliplatin caused by Olsalazine mediated nephrotoxicity. Ulcerative colitis [DD71] [19]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Astemizole. Vasomotor/allergic rhinitis [CA08] [17]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [55]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Procainamide. Ventricular tachyarrhythmia [BC71] [17]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Propafenone. Ventricular tachyarrhythmia [BC71] [17]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Flecainide. Ventricular tachyarrhythmia [BC71] [17]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Amiodarone. Ventricular tachyarrhythmia [BC71] [17]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Oxaliplatin and Ganciclovir. Virus infection [1A24-1D9Z] [15]
Valaciclovir DMHKS94 Moderate Increased risk of nephrotoxicity by the combination of Oxaliplatin and Valaciclovir. Virus infection [1A24-1D9Z] [20]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Valganciclovir. Virus infection [1A24-1D9Z] [15]
⏷ Show the Full List of 221 DDI Information of This Drug

References

1 Oxaliplatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21.
7 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
8 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
9 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
10 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
11 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
12 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
13 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
14 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17 Canadian Pharmacists Association.
18 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
19 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
25 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
28 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
29 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
30 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
31 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
32 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
33 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
34 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
35 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
36 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
37 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
38 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
40 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
41 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
44 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
45 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
46 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
47 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
48 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
50 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
51 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
53 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
54 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
55 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
56 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
57 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
58 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
59 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
60 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
61 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
62 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
63 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
64 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
65 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]